BICYCLIC HETEROCYCLES AS FGFR INHIBITORS

Description

FIELD OF THE INVENTION

The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the enzyme FGFR3 and are useful in the treatment of FGFR3-associated diseases such as cancer.

BACKGROUND OF INVENTION

The Fibroblast Growth Factor Receptors (FGFR) are receptor tyrosine kinases that bind to fibroblast growth factor (FGF) ligands. There are four FGFR proteins (FGFR1-4) that are capable of binding ligands and are involved in the regulation of many physiological processes including tissue development, angiogenesis, wound healing, and metabolic regulation. Upon ligand binding, the receptors undergo dimerization and phosphorylation leading to stimulation of the protein kinase activity and recruitment of many intracellular docking proteins. These interactions facilitate the activation of an array of intracellular signaling pathways including Ras-MAPK, AKT-PI3K, and phospholipase C that are important for cellular growth, proliferation and survival (Reviewed in Eswarakumar et al. Cytokine & Growth Factor Reviews, 2005, 16, 139-149). Aberrant activation of this pathway either through overexpression of FGF ligands or FGFR or activating mutations in the FGFRs can lead to tumor development, progression, and resistance to conventional cancer therapies. In human cancer, genetic alterations including gene amplification, chromosomal translocations and somatic mutations that lead to ligand-independent receptor activation have been described (Reviewed in Knights and Cook, Pharmacology & Therapeutics, 2010, 125, 105-117; Turner and Grose, Nature Reviews Cancer, 2010, 10, 116-129). Large scale DNA sequencing of thousands of tumor samples has revealed that FGFR genes are altered in many cancers (Helsten et al. Clin Cancer Res. 2016, 22, 259-267). Some of these activating mutations are identical to germline mutations that lead to skeletal dysplasia syndromes (Gallo et al. Cytokine & Growth Factor Reviews 2015, 26, 425-449). Mechanisms that lead to aberrant ligand-dependent signaling in human disease include overexpression of FGFs and changes in FGFR splicing that lead to receptors with more promiscuous ligand binding abilities. Therefore, development of inhibitors targeting FGFR may be useful in the clinical treatment of diseases that have elevated FGF or FGFR activity.

The cancer types in which FGF/FGFRs are implicated include, but are not limited to: carcinomas (e.g., bladder, breast, colorectal, endometrial, gastric, head and neck, kidney, lung, ovarian, prostate); hematopoietic malignancies (e.g., multiple myeloma, acute myelogenous leukemia, and myeloproliferative neoplasms); and other neoplasms (e.g., glioblastoma and sarcomas). In addition to a role in oncogenic neoplasms, FGFR activation has also been implicated in skeletal and chondrocyte disorders including, but not limited to, achrondroplasia and craniosynostosis syndromes.

There is a continuing need for the development of new drugs for the treatment of cancer, and the FGFR3 inhibitors described herein help address this need.

SUMMARY OF INVENTION

The present disclosure is directed to compounds having Formula (I):

embedded image

or pharmaceutically acceptable salts thereof, wherein constituent variables are defined herein.

The present disclosure is further directed to pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

The present disclosure is further directed to methods of inhibiting an FGFR3 enzyme comprising contacting the enzyme with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The present disclosure is further directed to a method of treating a disease associated with abnormal activity or expression of an FGFR3 enzyme, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

The present disclosure is further directed to compounds of Formula (I) for use in treating a disease associated with abnormal activity or expression of an FGFR3 enzyme.

The present disclosure is further directed to a method for treating a disorder mediated by an FGFR3 enzyme, or a mutant thereof, in a patient in need thereof, comprising the step of administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with another therapy or therapeutic agent as described herein.

The present disclosure is further directed to the use of compounds of Formula (I) in the preparation of a medicament for use in therapy.

DETAILED DESCRIPTION
Compounds

In one aspect, the present disclosure provides compounds of Formula (I):

embedded image

or a pharmaceutically acceptable salt thereof, wherein:

Cy¹is selected from:

- (i) phenyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;
- (ii) 5-membered heteroaryl, wherein the 5-membered heteroaryl has at least one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from O, S and N; wherein no more than 2 of the ring-forming heteroatoms of the 5-membered heteroaryl is N; wherein each N and S of the 5-membered heteroaryl is optionally oxidized; wherein a ring-forming carbon atom of the 5-membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;
- (iii) 6-membered heteroaryl, wherein the 6-membered heteroaryl has at least one ring-forming carbon atom, and 1, 2, or 3 ring-forming N atoms; wherein each N of the 6-membered heteroaryl is optionally oxidized; wherein a ring-forming carbon atom of the 6-membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 6-membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

Cy^Ais selected from C_6-10aryl and 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein each N and S is optionally oxidized; wherein a ring-forming carbon atom of 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C_6-10aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰;

R¹is selected from halo, CN, C_1-6alkyl, C_3-4cycloalkyl, azetidinyl, OR^aand NR^cR^d; wherein the C_1-6alkyl, C_3-6cycloalkyl, and azetidinyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^g;

each R¹⁰is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene, 5-10 membered heteroaryl-C_1-3alkylene, halo, D, CN, NO₂, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, C(═NR^e1)R^d1, C(═NOR^a1)R^b1, C(═NR^e1)NR^c1R^d1, NR^c1C(═NR^e1)NR^c1R^d1, NR^c1S(O)R^b1, NR^c1S(O)₂R^b1, NR^c1S(O)₂NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)₂R^b1, and S(O)₂NR^c1R^d1; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene and 5-10 membered heteroaryl-C_1-3alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene, 5-10 membered heteroaryl-C_1-3alkylene, halo, D, CN, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)ORO, NR^c3S(O)R^a3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene and 5-10 membered heteroaryl-C_1-3alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R¹²is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-6cycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^a5, SR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5, NR^c5R^d5, NR^c5C(O)R^b5, NR^c5C(O)OR^a5, NR^c5S(O)R^b5, NR^c5S(O)₂R^b5, NR^c5S(O)₂NR^c5R^d5, S(O)R^b5, S(O)NR^c5R^d5, S(O)₂R^b5, and S(O)₂NR^c5R^d5; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-6cycloalkyl, C_6-10aryl, 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R²⁰is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, halo, D, CN, NO₂, OR^a2, SR^a2, C(O)R^b2, C(O)NR^c2R^d2, C(O)OR^a2, OC(O)R^b2, OC(O)NR^c2R^d2, NR^c2R^d2, NR^c2C(O)R^b2, NR^c2C(O)OR^a2, NR^c2C(O)NR^c2R^d2, C(═NR^e2)R^b2, C(═NOR^a2)R^b2, C(═NR^e2)NR^e2R^d2, NR^e2C(═NR^e2)NR^c2R^d2, NR^c2S(O)R^b2, NR^c2S(O)₂R^b2, NR^c2S(O)₂NR^c2R^d2, S(O)R^b2, S(O)NR^c2R^d2, S(O)₂R^b2, and S(O)₂NR^c2R^d2; wherein said C_1-6alkyl, C_2-6alkenyl, and C_2-6alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or two adjacent R²⁰substituents on the Cy^Aring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered cycloalkyl ring or fused 5- or 6-membered heterocycloalkyl ring, wherein each fused 5- or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, or 3 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6-membered cycloalkyl ring and fused 5- or 6-membered heterocycloalkyl ring, are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹;

each R²¹is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, halo, D, CN, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)OR^a4, NR^c4S(O)R^b4, NR^c4S(O)₂R^b4, NR^c4S(O)₂NR^c4R^d4, S(O)R^b4, S(O)NR^c4R^d4, S(O)₂R^b4, and S(O)₂NR^c4R^d4; wherein said C_1-6alkyl, C_2-6alkenyl, and C_2-6alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

or two R²¹substituents taken together with the carbon atom to which they are attached form a spiro 3-7-membered heterocycloalkyl ring, or a spiro C_3-6cycloalkyl ring; wherein each spiro 3-7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each spiro 3-7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the spiro 3-7-membered heterocycloalkyl ring and spiro C_3-6cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²²;

each R²²is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^a6, SR^a6, C(O)R^b6, C(O)NR^c6R^d6, C(O)OR^a6, NR^c6R^d6, NR^c6C(O)R^b6, NR^c6C(O)OR^a6, NR^c6S(O)R^b6, NR^c6S(O)₂R^b6, NR^c6S(O)₂NR^c6R^d6, S(O)R^b6, S(O)NR^c6R^d6, S(O)₂R^b6, and S(O)₂NR^c6R^d6; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^a1, R^c1and R^d1is independently selected from H, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl and C_1-6haloalkyl; wherein said C_1-6alkyl, C_2-6alkenyl and C_2-6alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^a1, R^c1and R^d1is independently selected from H, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl and 5-10 membered heteroaryl; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

or any R^c1and R^d1attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R^b1is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl and 5-10 membered heteroaryl; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R^e1is independently selected from H, CN, C_1-6alkyl, C_1-6haloalkyl, C_1-6alkylthio, C_1-6alkylsulfonyl, C_1-6alkylcarbonyl, C_1-6alkylaminosulfonyl, carbamyl, C_1-6alkylcarbamyl, di(C_1-6alkyl)carbamyl, aminosulfonyl, C_1-6alkylaminosulfonyl and di(C_1-6alkyl)aminosulfonyl;

each R^a2, R^c2and R^d2is independently selected from H, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl and 5-10 membered heteroaryl; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or any R^c2and R^d2attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R²¹;

each R^b2is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl and 5-10 membered heteroaryl; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

each R^e2is independently selected from H, CN, C_1-6alkyl, C_1-6haloalkyl, C_1-6alkylthio, C_1-6alkylsulfonyl, C_1-6alkylcarbonyl, C_1-6alkylaminosulfonyl, carbamyl, C_1-6alkylcarbamyl, di(C_1-6alkyl)carbamyl, aminosulfonyl, C_1-6alkylaminosulfonyl and di(C_1-6alkyl)aminosulfonyl;

each R^a3, R^c3and R^d3is independently selected from H, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C_1-6alkyl C_2-6alkenyl, C_2-6alkynyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²;

or any R^c3and R^d3attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R²;

each R^b3is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C_1-6alkyl C_2-6alkenyl, C_2-6alkynyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²;

each R^a4, R^c4and R^d4is independently selected from H, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C_1-6alkyl C_2-6alkenyl, C_2-6alkynyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

or any R^c4and R^d4attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R²²;

each R^b4is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C_1-6alkyl C_2-6alkenyl, C_2-6alkynyl, C_3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

each R^a5, R^c5and R^d5is independently selected from H, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl and C_1-6haloalkyl; wherein said C_1-6alkyl, C_2-6alkenyl and C_2-6alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

or any R^c5and R^d5attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^b5is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl and C_1-6haloalkyl; wherein said C_1-6alkyl C_2-6alkenyl and C_2-6alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^a6, R^c6and R^d6is independently selected from H, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl and C_1-6haloalkyl; wherein said C_1-6alkyl, C_2-6alkenyl and C_2-6alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g; each R⁶is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, and C_1-6haloalkyl; wherein said C_1-6alkyl, C_2-6alkenyl and C_2-6alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g; and

each R^gis independently selected from OH, NO₂, CN, halo, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-6cycloalkyl, C_3-6cycloalkyl-C_1-2alkylene, C_1-6alkoxy, C_1-6haloalkoxy, C_1-3alkoxy-C_1-3alkyl, C_1-3alkoxy-C_1-3alkoxy, HO—C_1-3alkoxy, HO—C_1-3alkyl, cyano-C_1-3alkyl, H₂N—C_1-3alkyl, amino, C_1-6alkylamino, di(C_1-6alkyl)amino, thio, C_1-6alkylthio, C_1-6alkylsulfinyl, C_1-6alkylsulfonyl, carbamyl, C_1-6alkylcarbamyl, di(C_1-6alkyl)carbamyl, carboxy, C_1-6alkylcarbonyl, C_1-6alkoxycarbonyl, C_1-6alkylcarbonylamino, C_1-6alkylsulfonylamino, aminosulfonyl, C_1-6alkylaminosulfonyl, di(C_1-6alkyl)aminosulfonyl, aminosulfonylamino, C_1-6alkylaminosulfonylamino, di(C_1-6alkyl)aminosulfonylamino, aminocarbonylamino, C_1-6alkylaminocarbonylamino, and di(C_1-6alkyl)aminocarbonylamino.

In some embodiments, when Cy¹is phenyl, then R¹is other than halo.

In some embodiments, Cy¹is 5-membered heteroaryl, wherein the 5-membered heteroaryl has at least one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from O, S and N; wherein no more than 2 of the ring forming heteroatoms of the 5-membered heteroaryl is N; wherein each N and S of the 5-membered heteroaryl is optionally oxidized; wherein a ring-forming carbon atom of 5-membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is 5 or 6-membered heteroaryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is 5-membered heteroaryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹.

In some embodiments, Cy¹is 5-membered heteroaryl optionally substituted with 1 substituent selected from R¹⁰.

In some embodiments, Cy¹is 5-membered heteroaryl substituted with 1 substituent selected from R¹⁰.

In some embodiments, Cy¹is pyrazolyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is pyrazolyl optionally substituted with 1 or 2 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is pyrazolyl optionally substituted with 1 substituent selected from R¹⁰.

In some embodiments, Cy¹is pyrazolyl.

In some embodiments, Cy¹is pyrazolyl substituted with 1 substituent selected from R¹⁰.

In some embodiments, Cy¹is 6-membered heteroaryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is pyridinyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is pyridinyl optionally substituted with 1 substituent selected from R¹⁰.

In some embodiments, Cy¹is phenyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is phenyl optionally substituted with 1 substituent selected from R¹⁰.

In some embodiments, Cy¹is selected from pyrazolyl, pyridinyl, and phenyl; each of which is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is selected from pyrazolyl, pyridinyl, and phenyl; each of which is optionally substituted with 1 substituent selected from R¹⁰.

In some embodiments, Cy¹is selected from pyrazolyl, pyridinyl, and phenyl; each of which is substituted with R¹⁰.

In some embodiments, Cy¹is selected from pyrazolyl and pyridinyl, each of which is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is selected from pyrazol-4-yl, pyridine-3-yl, and phenyl; each of which is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹is selected from pyrazol-4-yl, pyridine-3-yl, and phenyl; each of which is optionally substituted with 1 substituent selected from R¹⁰.

In some embodiments, Cy¹is pyrazol-4-yl, optionally substituted with 1 substituent selected from R¹⁰.

In some embodiments, Cy¹is pyrazol-4-yl, substituted with 1 substituent selected from R¹⁰.

In some embodiments, each R¹⁰is independently selected from C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene, 5-10 membered heteroaryl-C_1-3alkylene, halo, CN, NO₂, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, NR^c1S(O)R^b1, NR^c1S(O)₂R^b1, NR^c1S(O)₂NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)₂R^b1, and S(O)₂NR^c1R^d1; wherein said C_1-6alkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene and 5-10 membered heteroaryl-C_1-3alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, each R¹⁰is independently selected from C_1-6alkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹⁰. In some embodiments, each R¹⁰is independently selected from C_1-6alkyl, C_3-6cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, each R¹⁰is independently selected from C_1-6alkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl; each of which is optionally substituted with 1 substituent selected from R¹⁰. In some embodiments, each R¹⁰is independently selected from C_1-6alkyl, C_3-6cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl; each of which is optionally substituted with 1 substituent selected from R¹⁰.

In some embodiments, R¹⁰is C_1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, R¹⁰is C_1-6alkyl optionally substituted with 1 substituent selected from R¹¹.

In some embodiments, R¹⁰is C_1-6alkyl.

In some embodiments, R¹⁰is C_3-10cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹. In some embodiments, R¹⁰is C_3-6cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, R¹⁰is C_3-10cycloalkyl. In some embodiments, R¹⁰is C_3-6cycloalkyl.

In some embodiments, R¹⁰is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹⁰. In some embodiments, R¹⁰is 4-6 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, R¹⁰is 4-10 membered heterocycloalkyl optionally substituted with 1 substituent selected from R¹⁰. In some embodiments, R¹⁰is 4-6 membered heterocycloalkyl optionally substituted with 1 substituent selected from R¹¹.

In some embodiments, R¹⁰is 4-10 membered heterocycloalkyl. In some embodiments, R¹⁰is 4-6 membered heterocycloalkyl.

In some embodiments, R¹⁰is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹⁰. In some embodiments, R¹⁰is 5-6 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, R¹⁰is 5-10 membered heteroaryl. In some embodiments, R¹⁰is 5-6 membered heteroaryl.

In some embodiments, each R¹⁰is independently selected from methyl, ethyl, propyl, cyclopropyl, cyclobutyl, piperazinyl, azetidinyl, piperidinyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, and pyridinyl; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, each R¹⁰is independently selected from methyl, propyl, 2-hydroxyethyl, cyclopropyl, cyclobutyl, CH₂C(O)NHCH₂CH₃, 4-acetylpiperazin-1-yl, 4-methylpiperazin-1-yl, 1-(dimethylcarbamoyl)azetidin-3-yl, 1-acetylpiperidin-4-yl, 4-methylpiperazin-1-yl, 1-(ethylcarbamoyl)azetidin-3-yl, 1-(methylsulfonyl)azetidin-3-yl, 1-acetylazetidin-3-yl, 1-methylpiperidin-4-yl, tetrahydro-2H-pyran-4-yl, tetrahydrofuran-3-yl, pyridin-2-ylmethyl, piperidin-4-ylmethyl, 2-morpholinoethyl, pyridin-3-ylmethyl, pyridin-2-yl, 1-(ethoxycarbonyl)azetidin-3-yl, 1-(methoxycarbonyl)piperidin-4-yl, and 1-(methoxycarbonyl)azetidin-3-yl.

In some embodiments, each R¹⁰is independently selected from methyl, ethyl, and propyl.

In some embodiments, R¹⁰is methyl.

In some embodiments, each R¹⁰is independently selected from cyclopropyl and cyclobutyl.

In some embodiments, each R¹⁰is independently selected from piperazinyl, azetidinyl, piperidinyl, tetrahydro-2H-pyranyl, and tetrahydrofuranyl.

In some embodiments, R¹⁰is pyridinyl.

In some embodiments, each R¹¹is independently selected from C_1-6alkyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3; wherein said C_1-6alkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²;

In some embodiments, each R¹¹is independently selected from C_1-6alkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, OR³, C(O)NR^c3R^d3, C(O)R^b3, C(O)OR^a3, and S(O)₂R^b3.

In some embodiments, each R¹¹is independently selected from C_1-6alkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, OR^a3, C(O)NR^c3R^d3, C(O)R^b3, C(O)OR^a3, and S(O)₂R^b3.

In some embodiments each R¹¹is independently selected from 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl.

In some embodiments, R¹¹is C_1-6alkyl.

In some embodiments, R¹¹is selected from C_1-6alkyl, OR^a3, C(O)NR^c3R^d3, C(O)R^b3, C(O)OR^a3, and S(O)₂R^b3.

In some embodiments, each R¹is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, D, CN, OR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5, NR^c5R^d5, and S(O)₂R^b5; wherein said C_1-6alkyl, is each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g.

In some embodiments, each R¹is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, CN, OR^a5, SR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5, NR^c5R^d5, NR^c5C(O)R^b5, NR^c5C(O)OR^a5, NR^c5S(O)₂R^b5, NR^c5S(O)₂NR^c5R^d5, S(O)₂R^b5, and S(O)₂NR^c5R^d5; wherein said C_1-6alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g.

In some embodiments, each R¹is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, CN, and OR^a5.

In some embodiments, Cy^Ais C_6-10aryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

In some embodiments, Cy^Ais phenyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

In some embodiments, Cy^Ais phenyl substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

In some embodiments, Cy^Ais phenyl optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰.

In some embodiments, Cy^Ais selected from 2,6-dimethylphenyl, 2-chloro-6-fluorophenyl, 2-chloro-6-methylphenyl, 2-methyl-6-(trifluoromethyl)phenyl, 4-fluoro-2,6-dimethylphenyl, 2-ethyl-6-methylphenyl, 2,6-diethylphenyl, 2-fluoro-6-methylphenyl, 2-methoxy-6-methylphenyl, 4-methoxy-2,6-dimethylphenyl, 4-cyano-2,6-dimethylphenyl, 2,6-dimethyl-4-(methylsulfonamido)phenyl, 4-acetamido-2,6-dimethylphenyl, and 4-(dimethylamino)-2,6-dimethylphenyl.

In some embodiments, Cy^Ais C_6-10aryl.

In some embodiments, Cy^Ais phenyl.

In some embodiments, Cy^Ais 5-10 membered heteroaryl optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰.

In some embodiments, Cy^Ais 5-6 membered heteroaryl optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰.

In some embodiments, each R²⁰is independently selected from C_1-6alkyl, C_2-6alkenyl, C₂₄alkynyl, C_1-6haloalkyl, halo, D, CN, NO₂, OR², SR², C(O)R^b2, C(O)NR^c2R^d2, C(O)OR², OC(O)R^b2, OC(O)NR^c2R^d2, NR^c2R^d2, NR^c2C(O)R^b2, NR^c2C(O)OR^a2, NR^c2C(O)NR^c2R^d2, NR^c2S(O)R^b2, NR^c2S(O)₂R^b2, NR^c2S(O)₂NR^c2R^d2, S(O)R^b2, S(O)NR^c2R^d2, S(O)₂R^b2, and S(O)₂NR^c2R^d2; wherein said C_1-6alkyl, C_2-6alkenyl, and C_2-6alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

In some embodiments, each R²⁰is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, CN, OR^a2, SR^a2, C(O)R^b2, C(O)NR^c2R^d2, C(O)OR^a2, OC(O)R^b2, OC(O)NR^c2R^d2, NR^c2R^d2, NR^c2C(O)R^b2, NR^c2C(O)OR, NR^c2C(O)NR^c2R^d2, NR^c2S(O)₂R^b2, NR^c2S(O)₂NR^c2R^d2, S(O)₂R^b2, and S(O)₂NR^c2R^d2; wherein said C_1-6alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

In some embodiments, each R²⁰is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, OR², CN, NR^c2R^d2, NR^c2C(O)R^b2, and NR^c2S(O)₂R^b2; wherein said C_1-6alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

In some embodiments, each R²⁰is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, OR, CN, NR^c2R^d2, NR^c2C(O)R^b2, and NR^c2S(O)₂R^b2.

In some embodiments, each R²⁰is independently selected from methyl, ethyl, methoxy, CF₃, CN, F, Cl, N(CH₃)₂, NHS(O)₂CH₃, and NHC(O)CH₃.

In some embodiments, two adjacent R²⁰substituents on the Cy^Aring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered cycloalkyl ring or fused 5- or 6-membered heterocycloalkyl ring, wherein each fused 5- or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1 or 2 ring-forming heteroatoms independently selected from N, O, and S; and wherein the fused 5- or 6-membered cycloalkyl ring and fused 5- or 6-membered heterocycloalkyl ring, are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹.

In some embodiments, each R²¹is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, D, CN, OR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, NR^c4R^d4and S(O)₂R; wherein said C_1-6alkyl, is each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²².

In some embodiments, each R²¹is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, CN, OR^a4, SR⁴and NR^c4R^d4; wherein said C_1-6alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²².

In some embodiments, each R²²is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, D, CN, OR^a6, and NR^c6R^d6; wherein said C_1-6alkyl, is each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g.

In some embodiments, each R²²is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, CN, OR^a6, SR^a6, C(O)R^b6, C(O)NR^c6R^d6, C(O)OR^a6, NR^c6R^d6, NR^c6C(O)R^b6, NR^c6C(O)OR^a6, NR^c6S(O)₂R^b6, NR^c6S(O)₂NR^c6R^d6, S(O)₂R^b6, and S(O)₂NR^c6R^d6; wherein said C_1-6alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g.

In some embodiments, each R²²is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, CN, OR, and NR^c6R^d6.

In some embodiments, R¹is selected from halo, CN, C_1-6alkyl, C_3-4cycloalkyl, azetidinyl, OR^aand NR^cR^d; wherein the C_1-6alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R^g.

In some embodiments, R¹is selected from halo, CN, C_1-3alkyl, and OR^a; wherein the C_1-6alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R^g.

In some embodiments, R¹is selected from halo, C_1-6alkyl, and OR^a.

In some embodiments, R¹is selected from halo, C_1-3alkyl, and OR^a.

In some embodiments, R¹is selected from Cl, methyl, and methoxy.

In some embodiments, R¹is OR^a.

In some embodiments, R¹is methoxy.

In some embodiments, R¹is C_1-6alkyl.

In some embodiments, R¹is methyl.

In some embodiments, R¹is halo.

In some embodiments, R¹is Cl.

In some embodiments, each R^a, R^cand R^dis independently selected from H and C_1-6alkyl.

In some embodiments, R is selected from H, C_1-3alkyl, and C_1-3haloalkyl.

In some embodiments, each R, R and R is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl; wherein said C_1-6alkyl, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, each R^b1is C_1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹. In some embodiments, each R^b1is C_1-6alkyl.

In some embodiments, each R^e1is independently selected from H, and C_1-6alkyl.

In some embodiments, each R^a2, R^c2and R^d2is independently selected from H and C_1-6alkyl.

In some embodiments, each R^a2, R^c2and R^d2, is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl; wherein said C_1-6alkyl.

In some embodiments, each R^b2is independently selected from C_1-6alkyl.

In some embodiments, each R^e2is independently selected from H and C_1-6alkyl.

In some embodiments, each R^a3, R^c3and R^d3is independently selected from H and C_1-6alkyl.

In some embodiments, each R^a3, R^c3and R^d3is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl.

In some embodiments, each R^b3is independently selected from C_1-6alkyl and C_1-6haloalkyl.

In some embodiments, each R^b3is C_1-6alkyl.

In some embodiments, each R^a4, R^c4and R^d4is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl.

In some embodiments, each R^a4, R^c4and R^d4is independently selected from H and C_1-6alkyl.

In some embodiments, each R^b4is independently selected from C_1-6alkyl.

In some embodiments, each R^a5, R^c5and R^d5is independently selected from H and C_1-6alkyl.

In some embodiments, each R^b5is independently selected from C_1-6alkyl.

In some embodiments, each R^a6, R^c6and R^d6is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl.

In some embodiments, each R^a6, R^c6and R^d6is independently selected from H and C_1-6alkyl.

In some embodiments, each R^b6is independently selected from C_1-6alkyl.

In some embodiments, each R^gis independently selected from OH, amino, CN, halo, and C_1-6alkyl.

In some embodiments, the compound of Formula (I) is a compound of Formula (IIa):

embedded image

or a pharmaceutically acceptable salt thereof, wherein Cy^A, R¹, and R¹⁰are as defined herein.

In some embodiments, the compound of Formula (I) is a compound of Formula (IIb):

embedded image

or a pharmaceutically acceptable salt thereof, wherein Cy^Aand R¹⁰are as defined herein.

In some embodiments, the compound of Formula (I) is a compound of Formula (IIIa):

embedded image

or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, or 3; and wherein R¹, R¹⁰, and R²⁰are as defined herein.

In some embodiments, the compound of Formula (I) is a compound of Formula (IIIb):

embedded image

or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, or 3; and wherein R¹⁰and R²⁰are as defined herein.

In some embodiments, the compound of Formula (I) is a compound of Formula (IV):

embedded image

or a pharmaceutically acceptable salt thereof, wherein Cy^Aand Cy¹are as defined herein.

In some embodiments, provided herein is a compound of Formula (I), wherein:

Cy¹is 5-membered heteroaryl, wherein the 5-membered heteroaryl has at least one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from 0, S and N; wherein no more than 2 of the ring forming heteroatoms of the 5-membered heteroaryl is N; wherein each N and S of the 5-membered heteroaryl is optionally oxidized; wherein a ring-forming carbon atom of 5-membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

Cy^Ais C_6-10aryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰;

R¹is selected from halo, CN, C_1-6alkyl, C_3-4cycloalkyl, azetidinyl, OR and NR^cR^d; wherein the C_1-6alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R^g;

each R¹⁰is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene, 5-10 membered heteroaryl-C_1-3alkylene, halo, D, CN, NO₂, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, C(═NR^e1)R^b1, C(═NOR^a1)R^b1, C(═NR^e1)NR^c1R^d1, NR^c1C(═NR^e1)NR^c1R^d1, NR^c1C(O)R^b1, NR^c1S(O)₂R^b1, NR^c1S(O)₂NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)₂R^b1, and S(O)₂NR^c1R^d1; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene and 5-10 membered heteroaryl-C_1-3alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene, 5-10 membered heteroaryl-C_1-3alkylene, halo, D, CN, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^b3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene and 5-10 membered heteroaryl-C_1-3alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²;

each R¹²is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-6cycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^a5, SR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5, NR^c5R^d5, NR^c5C(O)R^b5, NR^c5C(O)OR^a5, NR^c5S(O)R^b5, NR^c5S(O)₂R^b5, NRS(O)₂NR^c5R^d5, S(O)R^b5, S(O)NR^c5R^d5, S(O)₂R^b5, and S(O)₂NR^c5R^d5; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-6cycloalkyl, C_6-10aryl, 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R²⁰is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, halo, D, CN, NO₂, OR^a2, SR^a2, C(O)R^b2, C(O)NR^c2R^d2, C(O)OR^a2, OC(O)R^b2, OC(O)NR^c2R^d2, NR^c2R^d2, NR^c2C(O)R^b2, NR^c2C(O)OR^a2, NR^c2C(O)NR^c2R^d2, C(═NR^e2)R^b2, C(═NOR^a2)R^b2, C(═NR^e2)NR^c2R^d2, NR^c2C(═NR^e2)NR^c2R^d2, NR^c2S(O)R^b2, NR^c2S(O)₂R^b2, NR^c2S(O)₂NR^c2R^d2, S(O)R^b2, S(O)NR^c2R^d2, S(O)₂R^b2, and S(O)₂NR^c2R^d2; wherein said C_1-6alkyl, C_2-6alkenyl, and C_2-6alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

each R²¹is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, halo, D, CN, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)OR^a4, NR^c4S(O)R^b4, NR^c4S(O)₂R^b4, NR^c4S(O)₂NR^c4R^d4, S(O)R, S(O)NR^c4R^d4, S(O)₂R^b4, and S(O)₂NR^c4R^d4; wherein said C_1-6alkyl, C_2-6alkenyl, and C_2-6alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

or two R²¹substituents taken together with the carbon atom to which they are attached form a spiro 3-7-membered heterocycloalkyl ring, or a spiro C_3-6cycloalkyl ring; wherein each spiro 3-7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each spiro 3-7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the spiro 3-7 membered heterocycloalkyl ring and spiro C_3-6cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²²;

each R^a, R^cand R^dis independently selected from H, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl and C_1-6haloalkyl; wherein said C_1-6alkyl, C_2-6alkenyl and C_2-6alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^b6is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, and C_1-6haloalkyl; wherein said C_1-6alkyl, C_2-6alkenyl and C_2-6alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g; and

In some embodiments, when Cy¹is phenyl, then R¹is other than halo.

In some embodiments, provided herein is a compound of Formula (I), wherein:

Cy¹is pyrazolyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

Cy^Ais phenyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰;

R¹is selected from halo, CN, C_1-3alkyl, and OR^a; wherein the C_1-6alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R^g;

each R¹⁰is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene, 5-10 membered heteroaryl-C_1-3alkylene, halo, D, CN, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, NR^c1S(O)₂R^b1, NR^c1S(O)₂NR^c1R^d1, S(O)NR^c1R^d1, S(O)₂R^b1, and S(O)₂NR^c1R^d1; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, C_3-10cycloalkyl-C_1-3alkylene, 4-10 membered heterocycloalkyl-C_1-3alkylene, C_6-10aryl-C_1-3alkylene and 5-10 membered heteroaryl-C_1-3alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3; wherein said C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²;

each R¹²is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, D, CN, OR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5, NR^c5R^d5, and S(O)₂R^b5; wherein said C_1-6alkyl, is each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R²⁰is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, halo, D, CN, NO₂, OR^a2, SR^a2, C(O)R^b2, C(O)NR^c2R^d2, C(O)OR^a2, OC(O)R^b2, OC(O)NR^c2R^d2, NR^c2R^d2, NR^c2C(O)R^b2, NR^c2C(O)OR^a2, NR^c2C(O)NR^c2R^d2, NR^c2S(O)R^b2, NR^c2S(O)₂R^b2, NR^c2S(O)₂NR^c2R^d2, S(O)R^b2, S(O)NR^c2R^d2, S(O)₂R^b2, and S(O)₂NR^c2R^d2; wherein said C_1-6alkyl, C_2-6alkenyl, and C_2-6alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

each R²¹is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, D, CN, OR^a4, C(O)R, C(O)NR^c4R^d4, C(O)OR^a4, NR^c4R^d4, and S(O)₂R^b4; wherein said C_1-6alkyl, is each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²; each R²²is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, D, CN, OR⁶, and NR^c6R^d6; wherein said C_1-6alkyl, is each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

R^ais selected from H, C_1-3alkyl, and C1-3 haloalkyl;

each R^a4, R^c4and R^d4is independently selected from H, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl and C_1-6haloalkyl; wherein said C_1-6alkyl, C_2-6alkenyl and C_2-6alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

each R^b4is independently selected from C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, and C_1-6haloalkyl; wherein said C_1-6alkyl C_2-6alkenyl, and C_2-6alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

In some embodiments, provided herein is a compound of Formula (I), wherein:

Cy¹is pyrazolyl, pyridinyl, or phenyl, each of which is optionally substituted with 1 substituent selected from R⁰;

Cy^Ais phenyl optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰;

R¹is selected from halo, C_1-3alkyl, and OR^a;

each R¹⁰is independently selected from C_1-6alkyl, C_3-10cycloalkyl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl; each of which is optionally substituted with R¹¹;

R¹¹is independently selected from C_1-6alkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, OR^a3, C(O)NR^c3R^d3, C(O)R^b3, C(O)OR^a3, and S(O)₂R^b3;

each R²⁰is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, OR², CN, NR^c2R^d2, NR^c2C(O)R^b2, and NR^c2S(O)₂R^b2; wherein said C_1-6alkyl is optionally substituted with R²¹;

R²¹is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, CN, OR^a4, SR^a4and NR^c4R^d4; wherein said C_1-6alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

each R²²is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, CN, OR^a6, and NR^c6R^d6;

R^ais selected from H, C_1-3alkyl, and C_1-3haloalkyl;

each R^b2, R^c2and R^d2is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl; wherein said C_1-6alkyl;

each R^b2is independently selected from C_1-6alkyl;

each R^a3, R^c3and R^d3is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl;

each R^b3is independently selected from C_1-6alkyl and C_1-6haloalkyl;

each R^a4, R^c4and R^d4is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl; and

each R^a6, R^c6and R^d6is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl.

In some embodiments, provided herein is a compound of Formula (I) wherein:

Cy¹is pyrazolyl, pyridinyl, or phenyl, each of which is optionally substituted with R¹⁰;

Cy^Ais phenyl optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰;

R is selected from halo, C_1-3alkyl, and OR^a;

each R¹⁰is independently selected from C_1-6alkyl, C_3-10cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl; each of which is optionally substituted with R;

R¹¹is independently selected from C_1-6alkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, OR^a3, C(O)NR^c3R^d3, C(O)R^b3, C(O)OR^a3, and S(O)₂R^b3;

each R²⁰is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, OR^a2, CN, NR^c2R^d2, NR^c2C(O)R^b2, and NR^c2S(O)₂R^b2; wherein said C_1-6alkyl is optionally substituted with R²¹;

each R²²is independently selected from C_1-6alkyl, C_1-6haloalkyl, halo, CN, OR^a6, and NR^c6R^d6;

R^ais selected from H, C_1-3alkyl, and C_1-3haloalkyl;

each R^a2, R^c2and R^d2, is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl; wherein said C_1-6alkyl;

each R^b2is independently selected from C_1-6alkyl;

each R^a3, R^c3and R^d3is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl; each R^b3is independently selected from C_1-6alkyl and C_1-6haloalkyl;

each R^a4, R^c4and R^d4is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl; and

each R^a6, R^c6and R^d4is independently selected from H, C_1-6alkyl, and C_1-6haloalkyl.

In some embodiments, provided herein is a compound selected from:

N-(2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2-chloro-6-fluorophenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-5 carboxamide;
N-(2-chloro-6-methylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-6-(trifluoromethyl)phenyl)-1H-indazole-5-carboxamide;
N-(4-fluoro-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2-ethyl-6-methylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-diethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2-fluoro-6-methylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
6-methoxy-N-(2-methoxy-6-methylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
6-methoxy-N-(4-methoxy-2,6-dimethylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(4-cyano-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
6-chloro-N-(2,6-dimethylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2-fluoro-6-methylphenyl)-6-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
6-chloro-N-(2-fluoro-6-methylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
6-chloro-N-(2-chloro-6-fluorophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2-chloro-6-fluorophenyl)-3-(1-cyclobutyl-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;
N-(2-chloro-6-fluorophenyl)-3-(1-cyclopropyl-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-3-(1-(2-(ethylamino)-2-oxoethyl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;
3-(4-(4-acetylpiperazin-1-yl)phenyl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methoxy-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-indazole-5-carboxamide;
3-(1-(1-(dimethylcarbamoyl)azetidin-3-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;
ethyl 3-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate;
methyl 4-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate;
3-(1-(1-acetylpiperidin-4-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;
N-(2, 6-dimethylphenyl)-6-methoxy-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethyl-4-(methylsulfonamido)phenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(4-acetamido-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(4-(dimethylamino)-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-3-(1-(1-(ethylcarbamoyl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;
methyl 3-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate;
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(1-(methylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
3-(1-(1-acetylazetidin-3-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-3-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(piperidin-4-ylmethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;
3-(1-cyclobutyl-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;
3-(1-cyclopropyl-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide; and
N-(2,6-dimethylphenyl)-6-methoxy-3-(1-propyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide,
or a pharmaceutically acceptable of any of the aforementioned.

It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term “C_1-6alkyl” is specifically intended to individually disclose methyl, ethyl, C₃alkyl, C₄alkyl, C₅alkyl, and C₆alkyl.

At various places in the present specification various aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency. For example, the term “a pyridine ring” or “pyridinyl” may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring.

The term “n-membered” where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.

For compounds of the invention in which a variable appears more than once, each variable can be a different moiety independently selected from the group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound, the two R groups can represent different moieties independently selected from the group defined for R.

Definitions

As used herein, the phrase “optionally substituted” means unsubstituted or substituted.

The term “substituted” means that an atom or group of atoms formally replaces hydrogen as a “substituent” attached to another group. The term “substituted”, unless otherwise indicated, refers to any level of substitution, e.g., mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted. The substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule. A single divalent substituent, e.g., oxo, can replace two hydrogen atoms.

As used herein, the term “C_i-j,” where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range. For example, C_1-6alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.

As used herein, the term “alkyl,” employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched. An alkyl group formally corresponds to an alkane with one C—H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. In some embodiments, the alkyl group contains 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methyl-1-butyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, and the like. In some embodiments, the alkyl group is methyl, ethyl, or propyl.

As used herein, the term “C_i-jalkylene,” employed alone or in combination with other terms, means a saturated divalent linking hydrocarbon group that may be straight-chain or branched, having i to j carbons. In some embodiments, the alkylene group contains from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or from 1 to 2 carbon atoms. Examples of alkylene moieties include, but are not limited to, chemical groups such as methylene, ethylene, 1,1-ethylene, 1,2-ethylene, 1,3-propylene, 1,2-propylene, 1,1-propylene, isopropylene, and the like.

As used herein, “alkenyl,” employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more carbon-carbon double bonds. An alkenyl group formally corresponds to an alkene with one C—H bond replaced by the point of attachment of the alkenyl group to the remainder of the compound. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.

As used herein, “alkynyl,” employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more carbon-carbon triple bonds. An alkynyl group formally corresponds to an alkyne with one C—H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like.

As used herein, “halo” or “halogen”, employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or Cl. In some embodiments, halo is F.

As used herein, the term “haloalkyl,” employed alone or in combination with other terms, refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom, having up to the full valency of halogen atom substituents, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example haloalkyl groups include CF₃, C₂F₅, CHF₂, CCl₃, CHCl₂, C₂Cl₅, and the like.

As used herein, the term “alkoxy,” employed alone or in combination with other terms, refers to a group of formula —O-alkyl. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, alkoxy is methoxy.

As used herein, “haloalkoxy,” employed alone or in combination with other terms, refers to a group of formula —O-(haloalkyl). In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. An example haloalkoxy group is —OCF₃.

As used herein, “amino,” employed alone or in combination with other terms, refers to NH₂.

As used herein, the term “alkylamino,” employed alone or in combination with other terms, refers to a group of formula —NH(alkyl). In some embodiments, the alkylamino group has 1 to 6 or 1 to 4 carbon atoms. Example alkylamino groups include methylamino, ethylamino, propylamino (e.g., n-propylamino and isopropylamino), and the like.

As used herein, the term “dialkylamino,” employed alone or in combination with other terms, refers to a group of formula —N(alkyl)₂. Example dialkylamino groups include dimethylamino, diethylamino, dipropylamino (e.g., di(n-propyl)amino and di(isopropyl)amino), and the like. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term “alkylthio,” employed alone or in combination with other terms, refers to a group of formula —S-alkyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term “cycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups. The term “C_n-mcycloalkyl” refers to a cycloalkyl that has n to m ring member carbon atoms. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes. The term “cycloalkyl” also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-1-yl) and spirocycloalkyl groups (e.g., non-aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro[2.5]octane and the like). In some embodiments, the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members, or 3 to 6 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C_3-7monocyclic cycloalkyl group. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, tetrahydronaphthalenyl, octahydronaphthalenyl, indanyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

As used herein, the term “heterocycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus, and which has 4-14 ring members, 4-10 ring members, 4-7 ring members, or 4-6 ring members. Included within the term “heterocycloalkyl” are monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) or spirocyclic ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non-aromatic heterocycloalkyl ring, for example, 1,2,3,4-tetrahydro-quinoline and the like. Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan-1-yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [1,4-dioxa-8-aza-spiro[4.5]decan-N-yl] and the like). In some embodiments, the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, or 3 to 8 ring forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms. The carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, the heterocycloalkyl portion is a C_2-7monocyclic heterocycloalkyl group. In some embodiments, the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, dihydropyran ring, tetrahydropyran ring, tetrahyropyridine, azetidine ring, or tetrahydrofuran ring. In some embodiments, the heterocycloalkyl is a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S. In some embodiments, the heterocycloalkyl is 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S.

As used herein, the term “aryl,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 fused rings) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl.

As used herein, the term “heteroaryl” or “heteroaromatic” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 or 3 fused rings) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl, pyridone, or the like. The carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved. In one embodiment the heteroaryl group is a 5 to 10 membered heteroaryl group. In another embodiment the heteroaryl group is a 5 to 6 membered heteroaryl group. In some embodiments, the heteroaryl is a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S. In some embodiments, the heteroaryl is a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, no more than 2 heteroatoms of a 5-membered heteroaryl moiety are N.

A five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S. Exemplary five-membered ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.

A six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S. Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, isoindolyl, and pyridazinyl.

The term “oxo” refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to carbon, or attached to a heteroatom forming a sulfoxide or sulfone group, or an N-oxide group. In some embodiments, heterocyclic groups may be optionally substituted by 1 or 2 oxo (═O) substituents.

The term “oxidized” in reference to a ring-forming N atom refers to a ring-forming N-oxide.

The term “oxidized” in reference to a ring-forming S atom refers to a ring-forming sulfonyl or ring-forming sulfinyl.

The term “aromatic” refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character (i.e., having (4n+2) delocalized π (pi) electrons where n is an integer).

At certain places, the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3-position.

The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C═N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.

Resolution of racemic mixtures of compounds can be carried out by methods known in the art. An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.

Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.

In some embodiments, the compounds of the invention have the (R)-configuration. In other embodiments, the compounds have the (S)-configuration. In compounds with more than one chiral centers, each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated.

Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, enamine-imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.

Compounds of the invention also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 deuterium atoms. Synthetic methods for including isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, N.Y., Appleton-Century-Crofts, 1971; The Renaissance of H/D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of Isotopic Labelling by James R Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can used in various studies such as NMR spectroscopy, metabolism experiments, and/or assays.

Substitution with heavier isotopes such as deuterium, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. (A. Kerekes et.al. J. Med. Chem. 2011, 54, 201-210; R. Xu et.al. J. Label Compd Radiopharm. 2015, 58, 308-312).

The term, “compound,” as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted. The term is also meant to refer to compounds of the inventions, regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.

All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated. When in the solid state, the compounds described herein and salts thereof may occur in various forms and may, e.g., take the form of solvates, including hydrates. The compounds may be in any solid state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid state form of the compound.

In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By “substantially isolated” is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.

The following abbreviations may be used herein: AcOH (acetic acid); Ac₂O (acetic anhydride); aq. (aqueous); atm. (atmosphere(s)); Boc (t-butoxycarbonyl); br (broad); Cbz (carboxybenzyl); calc. (calculated); d (doublet); dd (doublet of doublets); DCM (dichloromethane); DEAD (diethyl azodicarboxylate); DIAD (N,N′-diisopropyl azidodicarboxylate); DIPEA (N,N-diisopropylethylamine); DMF (N,N-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g (gram(s)); h (hour(s)); HATU (N,N,N′,N-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate); HCl (hydrochloric acid); HPLC (high performance liquid chromatography); Hz (hertz); J (coupling constant); LCMS (liquid chromatography-mass spectrometry); m (multiplet); M (molar); mCPBA (3-chloroperoxybenzoic acid); MgSO₄(magnesium sulfate); MS (Mass spectrometry); Me (methyl); MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min. (minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal); NaHCO₃(sodium bicarbonate); NaOH (sodium hydroxide); Na₂SO₄(sodium sulfate); NH₄Cl (ammonium chloride); NH₄OH (ammonium hydroxide); NIS (N-iodosuccinimide); nM (nanomolar); NMR (nuclear magnetic resonance spectroscopy); OTf (trifluoromethanesulfonate); Pd (palladium); Ph (phenyl); μM (picomolar); PMB (para-methoxybenzyl), POCl₃(phosphoryl chloride); RP-HPLC (reverse phase high performance liquid chromatography); s (singlet); SEM (2-trimethylsilylethoxymethyl); t (triplet or tertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (triplet of triplets); t-Bu (tert-butyl); TFA (trifluoroacetic acid); THF (tetrahydrofuran); μg (microgram(s)); μL (microliter(s)); μM (micromolar); wt % (weight percent).

Synthesis

Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and according to various possible synthetic routes.

The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.

Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.

Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., ¹H or ¹³C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

The expressions, “ambient temperature,” “room temperature,” and “r.t.”, as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20° C. to about 30° C.

Compounds described herein can be prepared by one skilled in the art according to preparatory routes known in the literature. Example synthetic methods for preparing compounds of the invention are provided in the Schemes below.

embedded image

Compounds of formula (I) can be prepared using a process as illustrated in Scheme 1. In the process depicted in Scheme 1, compounds of formula 1-1 can be halogenated with one of the halogenation agents (e.g., NIS or iodine), followed by NH protection with a suitable protecting group (e.g., SEM or PMB), to afford compounds of formula 1-2. The cross-coupling reaction of 1-2, including Suzuki (Tetrahedron 2002, 58, 9633-9695) (e.g., in the presence of a palladium catalyst, such as Xphos Pd G2, and a base, such as potassium phosphate), Negishi (ACS Catalysis 2016, 6, 1540-1552) or Stille (ACS Catalysis 2015, 5, 3040-3053) (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) and others, results in compounds of formula 1-3. An ester group in the compounds of formula 1-3 can be hydrolyzed in basic conditions (e.g., LiOH or NaOH) to give compounds of formula 1-4. The compounds of the formula 1-4 can be coupled to an amine, HNCy^A, using standard amide coupling agents (e.g., HBTU, HATU or EDC) or via acid chloride formation (e.g., via reaction with SOCl₂or oxalyl chloride in a presence of DMF). Following deprotection of the protecting group, e.g. under acidic conditions, such as treatment with HCl or TFA, results in the formation of the desired compounds of formula (I).

Alternatively, an ester group in the compounds of formula 1-2 can be hydrolyzed in basic conditions (e.g., LiOH or NaOH) to give compounds of formula 1-5. The compounds of the formula 1-5 can be coupled to an amine, HNCy^A, using standard amide coupling agents (e.g., HBTU, HATU or EDC) or via acid chloride formation (e.g., via reaction with SOCl₂or oxalyl chloride in a presence of DMF), resulting in the formation of compounds of formula 1-6. The cross-coupling reaction of 1-6, including Suzuki (e.g., in the presence of a palladium catalyst, such as Xphos Pd G2, and a base, such as potassium phosphate), Negishi or Stille (e.g., in the presence of a palladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) and others, followed by deprotection of the protecting group, e.g. under acidic conditions, such as treatment with HCl or TFA, results in the formation of the desired compounds of formula (I).

Methods of Use

Compounds of the present disclosure can inhibit the activity of the FGFR enzyme. For example, compounds of the present disclosure can be used to inhibit activity of an FGFR enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient.

As FGFR inhibitors, the compounds of the present disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of the FGFR enzyme or FGFR ligands. Compounds which inhibit FGFR will be useful in providing a means of preventing the growth or inducing apoptosis in tumors, particularly by inhibiting angiogenesis. It is therefore anticipated that compounds of the present disclosure will prove useful in treating or preventing proliferative disorders such as cancers. In particular, tumors with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to the inhibitors.

In certain embodiments, the disclosure provides a method for treating a FGFR-mediated disorder in a patient in need thereof, comprising the step of administering to said patient a compound according to the invention, or a pharmaceutically acceptable composition thereof.

In some embodiments, diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.

Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET), 8p11 myeloproliferative syndrome), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, adult T-cell leukemia, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, marginal zone lymphoma, chronic myelogenic lymphoma and Burkitt's lymphoma.

Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, lymphosarcoma, leiomyosarcoma, and teratoma.

Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, pavicellular and non-pavicellular carcinoma, bronchial adenoma and pleuropulmonary blastoma.

Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (exocrine pancreatic carcinoma, ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colorectal cancer, gall bladder cancer and anal cancer.

Exemplary genitourinary tract cancers include cancers of the kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma) and urothelial carcinoma.

Exemplary liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors

Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors, neuro-ectodermal tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), neuroblastoma, Lhermitte-Duclos disease and pineal tumors.

Exemplary gynecological cancers include cancers of the breast (ductal carcinoma, lobular carcinoma, breast sarcoma, triple-negative breast cancer, HER2-positive breast cancer, inflammatory breast cancer, papillary carcinoma), uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma).

Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.

Exemplary head and neck cancers include glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinomas, adenocarcinomas, oral cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancers, thyroid and parathyroid cancers, tumors of the eye, tumors of the lips and mouth and squamous head and neck cancer.

The compounds of the present disclosure can also be useful in the inhibition of tumor metastases.

In addition to oncogenic neoplasms, the compounds of the invention are useful in the treatment of skeletal and chondrocyte disorders including, but not limited to, achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes. In some embodiments, the present disclosure provides a method for treating a patient suffering from a skeletal and chondrocyte disorder.

In some embodiments, compounds described herein can be used to treat Alzheimer's disease, HIV, or tuberculosis.

As used herein, the term “8p11 myeloproliferative syndrome” is meant to refer to myeloid/lymphoid neoplasms associated with eosinophilia and abnormalities of FGFR1.

As used herein, the term “cell” is meant to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal.

As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” the FGFR enzyme with a compound described herein includes the administration of a compound described herein to an individual or patient, such as a human, having FGFR, as well as, for example, introducing a compound described herein into a sample containing a cellular or purified preparation containing the FGFR enzyme.

As used herein, the term “individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.

As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent such as an amount of any of the solid forms or salts thereof as disclosed herein that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. An appropriate “effective” amount in any individual case may be determined using techniques known to a person skilled in the art.

The phrase “pharmaceutically acceptable” is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used herein, the phrase “pharmaceutically acceptable carrier or excipient” refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients or carriers are generally safe, non-toxic and neither biologically nor otherwise undesirable and include excipients or carriers that are acceptable for veterinary use as well as human pharmaceutical use. In one embodiment, each component is “pharmaceutically acceptable” as defined herein. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, Fla., 2009.

As used herein, the term “treating” or “treatment” refers to inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology) or ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment (while the embodiments are intended to be combined as if written in multiply dependent form). Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

Combination Therapy

One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., IL2, GM-CSF, etc.), and/or tyrosine kinase inhibitors can be used in combination with compounds described herein for treatment of FGFR-associated diseases, disorders or conditions, or diseases or conditions as described herein. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

Compounds described herein can be used in combination with one or more other kinase inhibitors for the treatment of diseases, such as cancer, that are impacted by multiple signaling pathways. For example, a combination can include one or more inhibitors of the following kinases for the treatment of cancer: Akt1, Akt2, Akt3, TGF-βR, Pim, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-IR, IR-R, PDGFαR, PDGFβR, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. Additionally, the solid forms of the FGFR inhibitor as described herein can be combined with inhibitors of kinases associated with the PIK3/Akt/mTOR signaling pathway, such as PI3K, Akt (including Akt1, Akt2 and Akt3) and mTOR kinases.

In some embodiments, compounds described herein can be used in combination with one or more inhibitors of the enzyme or protein receptors such as HPK1, SBLB, TUT4, A2A/A2B, CD47, CDK2, STING, ALK2, LIN28, ADAR1, MAT2a, RIOK1, HDAC8, WDR5, SMARCA2, and DCLK1 for the treatment of diseases and disorders. Exemplary diseases and disorders include cancer, infection, inflammation and neurodegenerative disorders.

In some embodiments, compounds described herein can be used in combination with a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulators include bromodomain inhibitors, the histone lysine methyltransferases, histone arginine methyl transferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases. Histone deacetylase inhibitors include, e.g., vorinostat.

For treating cancer and other proliferative diseases, compounds described herein can be used in combination with targeted therapies, including JAK kinase inhibitors (Ruxolitinib, additional JAK1/2 and JAK1-selective, baricitinib or INCB39110), Pim kinase inhibitors (e.g., LGH447, INCB053914 and SGI-1776), PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors (e.g., INCB50465 and INCB54707), PI3K-gamma inhibitors such as PI3K-gamma selective inhibitors, MEK inhibitors, CSF1R inhibitors (e.g., PLX3397 and LY3022855), TAM receptor tyrosine kinases inhibitors (Tyro-3, Axl, and Mer; e.g., INCB81776), angiogenesis inhibitors, interleukin receptor inhibitors, Cyclin Dependent kinase inhibitors, BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (Bortezomib, Carfilzomib), HDAC-inhibitors (panobinostat, vorinostat), DNA methyl transferase inhibitors, dexamethasone, bromo and extra terminal family members inhibitors (for example, bromodomain inhibitors or BET inhibitors, such as OTX015, CPI-0610, INCB54329 or INCB57643), LSD1 inhibitors (e.g., GSK2979552, INCB59872 and INCB60003), arginase inhibitors (e.g., INCB1158), indoleamine 2,3-dioxygenase inhibitors (e.g., epacadostat, NLG919 or BMS-986205), PARP inhibiors (e.g., olaparib or rucaparib), and inhibitors of BTK such as ibrutinib.

For treating cancer and other proliferative diseases, compounds described herein can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti-proliferative agents. Compounds described herein can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes.

Examples of suitable chemotherapeutic agents include any of: abarelix, abiraterone, afatinib, aflibercept, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amidox, amsacrine, anastrozole, aphidicolon, arsenic trioxide, asparaginase, axitinib, azacitidine, bevacizumab, bexarotene, baricitinib, bendamustine, bicalutamide, bleomycin, bortezombi, bortezomib, brivanib, buparlisib, busulfan intravenous, busulfan oral, calusterone, camptosar, capecitabine, carboplatin, carmustine, cediranib, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dacomitinib, dactinomycin, dalteparin sodium, dasatinib, dactinomycin, daunorubicin, decitabine, degarelix, denileukin, denileukin diftitox, deoxycoformycin, dexrazoxane, didox, docetaxel, doxorubicin, droloxafine, dromostanolone propionate, eculizumab, enzalutamide, epidophyllotoxin, epirubicin, epothilones, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, flutamide, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, idelalisib, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lonafarnib, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mithramycin, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, navelbene, necitumumab, nelarabine, neratinib, nilotinib, nilutamide, niraparib, nofetumomab, oserelin, oxaliplatin, paclitaxel, pamidronate, panitumumab, panobinostat, pazopanib, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pilaralisib, pipobroman, plicamycin, ponatinib, porfimer, prednisone, procarbazine, quinacrine, ranibizumab, rasburicase, regorafenib, reloxafine, revlimid, rituximab, rucaparib, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, tegafur, temozolomide, teniposide, testolactone, tezacitabine, thalidomide, thioguanine, thiotepa, tipifarnib, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, triapine, trimidox, triptorelin, uracil mustard, valrubicin, vandetanib, vinblastine, vincristine, vindesine, vinorelbine, vorinostat, veliparib, talazoparib, and zoledronate.

In some embodiments, compounds described herein can be used in combination with immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3 (e.g., INCAGN2385), TIM3 (e.g., INCB2390), VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40 (e.g., INCAGN1949), GITR (e.g., INCAGN1876) and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.

In some embodiments, the inhibitor of an immune checkpoint molecule is a small molecule PD-L1 inhibitor. In some embodiments, the small molecule PD-L1 inhibitor has an IC50 less than 1 μM, less than 100 nM, less than 10 nM or less than 1 nM in a PD-L1 assay described in US Patent Publication Nos. US 20170107216, US 20170145025, US 20170174671, US 20170174679, US 20170320875, US 20170342060, US 20170362253, and US 20180016260, each of which is incorporated by reference in its entirety for all purposes.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is MGA012, nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, ipilumimab or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab. In some embodiments, the anti-PD1 antibody is nivolumab. In some embodiments, the anti-PD-1 monoclonal antibody is MGA012. In some embodiments, the anti-PD1 antibody is SHR-1210. Other anti-cancer agent(s) include antibody therapeutics such as 4-1BB (e.g. urelumab, utomilumab.

In some embodiments, the compounds of the disclosure can be used in combination with INCB086550.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525, or INCAGN2385.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, or MEDI1873.

In some embodiments, the inhibitor of an immune checkpoint molecule is an agonist of OX40, e.g., OX40 agonist antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS-986178. In some embodiments, the OX40L fusion protein is MEDI6383.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.

The compounds of the present disclosure can be used in combination with bispecific antibodies. In some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3 or TGFβ receptor.

In some embodiments, the compounds of the disclosure can be used in combination with one or more metabolic enzyme inhibitors. In some embodiments, the metabolic enzyme inhibitor is an inhibitor of IDO1, TDO, or arginase. Examples of IDO inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.

In some embodiments, the salts of the compounds described herein can be used in combination with one or more agents for the treatment of diseases such as cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).

Suitable antiviral agents contemplated for use in combination with compounds of the present disclosure can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.

Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(−)-FTC]; beta-L-FD4 (also called beta-L-D4C and named beta-L-2′, 3′-dicleoxy-5-fluoro-cytidene); DAPD, ((−)-beta-D-2,6-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione); and (+)-calanolide A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1 549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No. 11607.

Suitable agents for use in combination with compounds described herein for the treatment of cancer include chemotherapeutic agents, targeted cancer therapies, immunotherapies or radiation therapy. Compounds described herein may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors. Suitable examples are anti-estrogen agents including but not limited to tamoxifen and toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megastrol acetate), and estrogen receptor antagonists (e.g. fulvestrant). Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds described herein. These include anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g. abiraterone).

The compounds described herein may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, or Flt-3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk. Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR/Her2 include but are not limited to dacomitinib, afatinib, lapitinib and neratinib. Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab. Inhibitors of c-Met may be used in combination with FGFR inhibitors. These include onartumzumab, tivantnib, and INC-280. Agents against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib and those against Alk (or EML4-ALK) include crizotinib.

Angiogenesis inhibitors may be efficacious in some tumors in combination with FGFR inhibitors. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti-angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib

Activation of intracellular signaling pathways is frequent in cancer, and agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance. Examples of agents that may be combined with compounds described herein include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of protein chaperones and cell cycle progression.

Agents against the PI3 kinase include but are not limited topilaralisib, idelalisib, buparlisib. Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with FGFR inhibitors. Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK inhibitors). Inhibitors of one or more JAKs (e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), HDACs (e.g., panobinostat), PARP (e.g., olaparib), and proteasomes (e.g., bortezomib, carfilzomib) can also be combined with compounds described herein. In some embodiments, the JAK inhibitor is selective for JAK1 over JAK2 and JAK3.

Other suitable agents for use in combination with compounds described herein include chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).

Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (Cytoxan™), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.

Other suitable agents for use in combination with compounds described herein include steroids including 17 alpha-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, and medroxyprogesteroneacetate.

Other suitable agents for use in combination with compounds described herein include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the “Dartmouth regimen,” which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide. Compounds described herein may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in.

Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.

Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (TAXOL™), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-α), etoposide, and teniposide.

Other cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.

Also suitable are cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.

Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4-1BB, PD-L1 and PD-1 antibodies, or antibodies to cytokines (IL-10, TGF-β, etc.).

Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.

Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.

Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses. In some embodiments, tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV). Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.

The compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.

Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the “Physicians' Desk Reference” (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, N.J.), the disclosure of which is incorporated herein by reference as if set forth in its entirety.

As provided throughout, the additional compounds, inhibitors, agents, etc. can be combined with the present compound in a single or continuous dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.

Pharmaceutical Formulations and Dosage Forms

When employed as pharmaceuticals, compounds described herein can be administered in the form of pharmaceutical compositions which refers to a combination of one or more compounds described herein, and at least one pharmaceutically acceptable carrier or excipient.

These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

This disclosure also includes pharmaceutical compositions which contain, as the active ingredient, one or more compounds described herein in combination with one or more pharmaceutically acceptable carriers or excipients. In making the compositions described herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In some embodiments, the composition is suitable for topical administration.

In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art see, e.g., WO 2002/000196.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.

In some embodiments, the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, the microcrystalline cellulose is Avicel PH102™. In some embodiments, the lactose monohydrate is Fast-flo 316™. In some embodiments, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g., Methocel K4 M Premier™) and/or hydroxypropyl methylcellulose 2208 K100LV (e.g., Methocel K00LV™). In some embodiments, the polyethylene oxide is polyethylene oxide WSR 1105 (e.g., Polyox WSR 1105™).

In some embodiments, a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition.

The compositions can be formulated in a unit dosage form, each dosage containing from, for example, about 5 mg to about 1000 mg, about 5 mg to about 100 mg, about 100 mg to about 500 mgor about 10 to about 30 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

The components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Particularly for human consumption, the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration. For example, suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good Manufacturing Practice regulations of the U.S. Food and Drug Administration.

The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

The therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of one or more compounds described herein. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present disclosure.

The tablets or pills of the present disclosure can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

The liquid forms in which the compounds, or compositions as described herein can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.

Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, e.g., liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g., glycerol, hydroxyethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt % of the compound of the invention. The topical formulations can be suitably packaged in tubes of, e.g., 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.

The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.

The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

The therapeutic dosage of a compound of the present disclosure can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of the compounds in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, compounds of the present disclosure can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

Compounds described herein can also be formulated in combination with one or more additional active ingredients, which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like.

Labeled Compounds and Assay Methods

Another aspect of the present invention relates to labeled compounds of the disclosure (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating FGFR3 protein in tissue samples, including human, and for identifying FGFR3 ligands by inhibition binding of a labeled compound. Substitution of one or more of the atoms of the compounds of the present disclosure can also be useful in generating differentiated ADME (Adsorption, Distribution, Metabolism and Excretion). Accordingly, the present invention includes FGFR binding assays that contain such labeled or substituted compounds.

The present disclosure further includes isotopically-labeled compounds of the disclosure. An “isotopically” or “radio-labeled” compound is a compound of the disclosure where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present disclosure include but are not limited to ²H (also written as D for deuterium), ³H (also written as T for tritium), ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ¹⁸F, ³⁵S, ³⁶Cl, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, ¹²⁵I and ¹³¹I. For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced by deuterium atoms (e.g., one or more hydrogen atoms of a C_1-6alkyl group of Formula (I) can be optionally substituted with deuterium atoms, such as —CD₃being substituted for —CH₃). In some embodiments, alkyl groups in Formula (I) can be perdeuterated.

One or more constituent atoms of the compounds presented herein can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1-2, 1-3, 1-4, 1-5, or 1-6 deuterium atoms. In some embodiments, all of the hydrogen atoms in a compound can be replaced or substituted by deuterium atoms.

Synthetic methods for including isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, N.Y., Appleton-Century-Crofts, 1971; The Renaissance of H/D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of Isotopic Labelling by James R. Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can be used in various studies such as NMR spectroscopy, metabolism experiments, and/or assays.

Substitution with heavier isotopes, such as deuterium, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. (see e.g., A. Kerekes et. al. J. Med. Chem. 2011, 54, 201-210; R. Xu et. al. J. Label Compd. Radiopharm. 2015, 58, 308-312). In particular, substitution at one or more metabolism sites may afford one or more of the therapeutic advantages.

The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro adenosine receptor labeling and competition assays, compounds that incorporate ¹³H, ¹⁴C, ⁸²Br, ¹²⁵I, ¹³¹I or ³⁵S can be useful. For radio-imaging applications ¹¹C, ¹⁸F, ¹²⁵I, ¹²³I, ¹²⁴I, ¹³¹L, ⁷⁵Br, ⁷⁶Br or ⁷⁷Br can be useful.

It is understood that a “radio-labeled” or “labeled compound” is a compound that has incorporated at least one radionuclide. In some embodiments, the radionuclide is selected from the group consisting of ¹³H, ¹⁴C, ¹²⁵I, ³⁵S and ⁸²Br.

The present disclosure can further include synthetic methods for incorporating radio-isotopes into compounds of the disclosure. Synthetic methods for incorporating radio-isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of disclosure.

A labeled compound of the invention can be used in a screening assay to identify and/or evaluate compounds. For example, a newly synthesized or identified compound (i.e., test compound) which is labeled can be evaluated for its ability to bind an FGFR3 protein by monitoring its concentration variation when contacting with the FGFR3, through tracking of the labeling. For example, a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a FGFR3 protein (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the FGFR3 protein directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.

Kits

The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of FGFR-associated diseases or disorders, such as cancer and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the disclosure. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.

The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of FGFR3 as described below.

EXAMPLES

Experimental procedures for compounds of the invention are provided below. All the starting materials are commercially available or readily synthezied according to procedures known in the art. Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. “Two-Pump At Column Dilution Configuration for Preparative LC-MS”, K. Blom, J. Combi. Chem., 4, 295 (2002); “Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification”, K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and “Preparative LC-MS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity check under the following conditions: Instrument; Agilent 1100 series, LC/MSD, Column: Waters Sunfire™ Cis 5 μm particle size, 2.1×5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% of B in 3 minutes with flow rate 2.0 mL/minute.

Some of the compounds prepared were also separated on a preparative scale by reverse-phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse-phase high performance liquid chromatography (RP-HPLC) column conditions are as follows:

pH=2 purifications: Waters Sunfire™ Cis 5 μm particle size, 19×100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 30 m/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see “Preparative LCMS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with the 30×100 mm column was 60 mL/minute.

pH=10 purifications: Waters XBridge Cis 5 μm particle size, 19×100 mm column, eluting with mobile phase A: 0.15% NH₄OH in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See “Preparative LCMS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with 30×100 mm column was 60 mL/minute.

The following abbreviations may be used herein: AcOH (acetic acid); Ac₂O (acetic anhydride); aq. (aqueous); atm. (atmosphere(s)); Boc (t-butoxycarbonyl); BOP ((benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate); br (broad); Cbz (carboxybenzyl); calc. (calculated); d (doublet); dd (doublet of doublets); DBU (1,8-diazabicyclo[5.4.0]undec-7-ene); DCM (dichloromethane); DIAD (N, N′-diisopropyl azidodicarboxylate); DIEA (N,N-diisopropylethylamine); DIPEA (N, N-diisopropylethylamine); DIBAL (diisobutylaluminium hydride); DMF (N, N-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); FCC (flash column chromatography); g (gram(s)); h (hour(s)); HATU (N, N, N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate); HCl (hydrochloric acid); HPLC (high performance liquid chromatography); Hz (hertz); J (coupling constant); LCMS (liquid chromatography-mass spectrometry); LDA (lithium diisopropylamide); m (multiplet); M (molar); mCPBA (3-chloroperoxybenzoic acid); MS (Mass spectrometry); Me (methyl); MCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min. (minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal); nM (nanomolar); NMP (N-methylpyrrolidinone); NMR (nuclear magnetic resonance spectroscopy); OTf (trifluoromethanesulfonate); Ph (phenyl); pM (picomolar); RP-HPLC (reverse phase high performance liquid chromatography); r.t. (room temperature), s (singlet); t (triplet or tertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (triplet of triplets); TFA (trifluoroacetic acid); THF (tetrahydrofuran); μg (microgram(s)); μL (microliter(s)); μM (micromolar); wt % (weight percent). Brine is saturated aqueous sodium chloride. In vacuo is under vacuum.

Example 1. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

Step 1. Methyl 6-methoxy-1H-indazole-5-carboxylate

embedded image

Sulfuric acid (1.00 ml, 18.76 mmol) was slowly added to a solution of 6-methoxy-1H-indazole-5-carboxylic acid (1.00 g, 5.20 mmol) in MeOH (20 ml) at 0° C. After stirring at r.t. for 18 h, the solvent was removed in vacuo and EtOAc was added. The resultant solution was washed with saturated NaHCO₃solution until the remaining acid was neutralized. The organic phase was further washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The resultant crude product was used in the next step without further purification. LC-MS calculated for C₁₀H₁₁N₂O₃(M+H)⁺: m/z=207.1; found 207.1.

Step 2. Methyl 3-iodo-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylate

embedded image

To a solution of methyl 6-methoxy-1H-indazole-5-carboxylate (1.04 g, 5.04 mmol) in DMF (10 ml) was added N-iodosuccinimide (1.362 g, 6.05 mmol). The reaction mixture was heated to 60° C. for 1 h and then cooled to r.t. DIPEA (1.1 ml, 6.05 mmol) was added, followed by SEM-Cl (0.984 ml, 5.55 mmol). After stirring at r.t. for 1 h, the reaction mixture was quenched with water and the desired product was extracted with EtOAc. The organic phase was washed with Na₂S₂O₃solution, dried over sodium sulfate and concentrated in vacuo. Crude material was purified by Biotage Isolera to give the desired product as yellow oil. LCMS calculated for C₁₆H₂₄IN₂O₄Si (M+H)⁺: m/z=463.1; found: 463.1.

Step 3. Methyl 6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylate

embedded image

To a mixture of methyl 3-iodo-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylate (0.600 g, 1.298 mmol), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium (XPhos Pd G2, 0.102 g, 0.130 mmol), K₃PO₄(0.331 g, 1.557 mmol) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.405 g, 1.947 mmol) were added 1,4-dioxane (10 ml) and water (2 ml). The reaction flask was evacuated, back filled with nitrogen, and stirred at 60° C. for 1 h. The reaction mixture was cooled to r.t., and the solvents were evaporated in vacuo. LCMS calculated for C₂₀H₂₉N₄O₄Si (M+H)⁺: m/z=417.2; found: 417.3.

Step 4. 6-Methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylic acid

embedded image

To a solution of methyl 6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylate (0.53 g, 1.272 mmol) in THF (7 ml) and methanol (7 ml) was added a 1M solution of sodium hydroxide (6.36 ml, 6.36 mmol). After stirring at r.t. for 1 h, the reaction mixture was neutralized to pH=5 with 1M HCl. The precipitated product was collected by filtration, washed with MeOH and ether, and then air-dried overnight. The resulting material was taken forward without additional purification. LCMS calculated for C₁₉H₂₇N₄O₄Si (M+H)⁺: m/z=403.2; found: 403.2.

Step 5. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

HATU (14.2 mg, 0.037 mmol) was added to a solution of 6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylic acid (10.0 mg, 0.025 mmol), 2,6-dimethylaniline (3.01 mg, 0.025 mmol) and DIPEA (8.68 μl, 0.050 mmol) in N,N-dimethylformamide (1.0 ml). After the reaction mixture was stirred at 50° C. for 1h, the solution was diluted with EtOAc, washed with brine, dried over sodium sulfate and the solvents were evaporated in vacuo. The resultant material was dissolved in a mixture of DCM (1 ml) and TFA (0.5 ml) and the solution was stirred at r.t. for 15 min. The solvents were evaporated in vacuo and the crude material was dissolved in MeOH (1 ml) and a water solution of ammonia (0.5 ml). The reaction mixture was stirred at r.t. for 10 min, then diluted with CH₃CN and water and purified by prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 m/min). The product was isolated as the TFA salt. LCMS calculated for C₂₁H₂₂N₅O₂(M+H)⁺: m/z=376.2; found: 376.2. ¹H NMR (500 MHz, DMSO-d6) δ 9.55-9.45 (s, 1H), 8.39-8.33 (s, 1H), 8.32-8.26 (s, 1H), 7.99-7.91 (s, 1H), 7.16-7.11 (s, 3H), 7.11-7.07 (s, 1H), 4.04-3.98 (s, 3H), 3.97-3.92 (s, 3H), 2.34-2.23 (s, 6H) ppm.

Example 2. N-(2-Chloro-6-fluorophenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 2-chloro-6-fluoroaniline replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₁₉H₁₆ClFN₅O₂(M+H)⁺: m/z=400.1; found: 400.1.

Example 3. N-(2-Chloro-6-methylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 2-chloro-6-methylaniline replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₂₀H₁₉ClN₅O₂(M+H)⁺: m/z=396.1; found: 396.2.

Example 4. 6-Methoxy-3-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-6-(trifluoromethyl)phenyl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 2-methyl-6-(trifluoromethyl)-aniline replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₂₁H₁₉F₃N₅O₂(M+H)⁺: m/z=430.2; found: 430.2.

Example 5. N-(4-Fluoro-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 4-fluoro-2,6-dimethylaniline replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₂₁H₂₁FN₅O₂(M+H)⁺: m/z=394.2; found: 394.2.

Example 6. N-(2-Ethyl-6-methylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 2-ethyl-6-methylaniline replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₂₂H₂₄N₅O₂(M+H)⁺: m/z=390.2; found: 390.3.

Example 7. N-(2,6-Diethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 2,6-diethylaniline replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₂₃H₂₆N₅O₂(M+H)⁺: m/z=404.2; found: 404.3.

Example 8. N-(2-Fluoro-6-methylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 2-fluoro-6-methylaniline replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₂₀H₁₉FN₅O₂(M+H)⁺: m/z=380.2; found: 380.2.

Example 9. 6-Methoxy-N-(2-methoxy-6-methylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 2-methoxy-6-methylaniline replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₂₁H₂₂N₅O₃(M+H)⁺: m/z=392.2; found: 392.2.

Example 10. 6-Methoxy-N-(4-methoxy-2,6-dimethylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 4-methoxy-2,6-dimethylaniline replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₂₂H₂₄N₅O₃(M+H)⁺: m/z=406.2; found: 406.3.

Example 11. N-(4-Cyno-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 4-amino-3,5-dimethylbenzonitrile replacing 2,6-dimethylaniline in Step 5. The product was isolated as the TFA salt. LCMS calculated for C₂₂H₂₁N₆O₂(M+H)⁺: m/z=401.2; found: 401.2.

Example 12. N-(2,6-Dimethylphenyl)-6-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 6-methyl-1H-indazole-5-carboxylic acid replacing 6-methoxy-1H-indazole-5-carboxylic acid in Step 1. The product was isolated as the TFA salt. LCMS calculated for C₂₁H₂₂N₅O (M+H)⁺: m/z=360.2; found: 360.2.

Example 13. 6-Chloro-N-(2,6-dimethylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 6-chloro-1H-indazole-5-carboxylic acid replacing 6-methoxy-1H-indazole-5-carboxylic acid in Step 1. The product was isolated as the TFA salt. LCMS calculated for C₂₀H₁₉ClN₅O (M+H)⁺: m/z=380.1; found: 380.2.

Example 14. N-(2-Fluoro-6-methylphenyl)-6-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 6-methyl-1H-indazole-5-carboxylic acid replacing 6-methoxy-1H-indazole-5-carboxylic acid and 2-fluoro-6-methylaniline replacing 2,6-dimethylaniline in Steps 1 and 5, respectively. The product was isolated as the TFA salt. LCMS calculated for C₂₀H₁₉FN₅O (M+H)⁺: m/z=364.2; found: 364.2.

Example 15. 6-Chloro-N-(2-fluoro-6-methylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 6-chloro-1H-indazole-5-carboxylic acid replacing 6-methoxy-1H-indazole-5-carboxylic acid and 2-fluoro-6-methylaniline replacing 2,6-dimethylaniline in Steps 1 and 5, respectively. The product was isolated as the TFA salt. LCMS calculated for C₁₉H₁₆ClFN₅O (M+H)⁺: m/z=384.1; found: 384.1.

Example 16. 6-Chloro-N-(2-chloro-6-fluorophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 6-chloro-1H-indazole-5-carboxylic acid replacing 6-methoxy-1H-indazole-5-carboxylic acid and 2-chloro-6-fluoroaniline replacing 2,6-dimethylaniline in Steps 1 and 5, respectively. The product was isolated as the TFA salt. LCMS calculated for C₁₈H₁₃Cl₂FN₅O (M+H)⁺: m/z=404.1; found: 404.1.

Example 17. N-(2-Chloro-6-fluorophenyl)-3-(1-cyclobutyl-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 1-cyclobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 2-chloro-6-fluoroaniline replacing 2,6-dimethylaniline in Steps 3 and 5, respectively. The product was isolated as the TFA salt. LCMS calculated for C₂₂H₂₀ClFN₅O₂(M+H)⁺: m/z=440.1; found: 440.2.

Example 18. N-(2-Chloro-6-fluorophenyl)-3-(1-cyclopropyl-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 1, with 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 2-chloro-6-fluoroaniline replacing 2,6-dimethylaniline in Steps 3 and 5, respectively. The product was isolated as the TFA salt. LCMS calculated for C₂₁H₁₈ClFN₅O₂(M+H)⁺: m/z=426.1; found: 426.2.

Example 19. N-(2,6-Dimethylphenyl)-3-(1-(2-(ethylamino)-2-oxoethyl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

Step 1. 3-Iodo-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylic acid

embedded image

A solution of methyl 3-iodo-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylate (Example 1, Step 2, 3.8 g, 8.22 mmol) and sodium hydroxide (1M solution in water, 41 ml, 41 mmol) in a mixture of THF (10 ml), MeOH (10 ml), and water (10 ml) was stirred at r.t. for 1 h. At completion, the pH of the reaction solution was adjusted to pH 5 using 1M HCl. The precipitate was collected by filtration, washed with MeOH and ether, and then air-dried overnight. The resulting material was taken forward without additional purification. LCMS calculated for C₁₅H₂₂IN₂O₄Si (M+H)⁺: m/z=449.1; found: 449.1.

Step 2. N-(2,6-Dimethylphenyl)-3-iodo-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxamide

embedded image

DIPEA (2.80 ml, 16.06 mmol) was added to a solution of 3-iodo-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylic acid (3.60 g, 8.03 mmol), 2,6-dimethylaniline (0.973 g, 8.03 mmol) and HATU (4.58 g, 12.04 mmol) in N,N-dimethylformamide (40.0 ml). The reaction mixture was stirred at 50° C. for 4 h. At completion, the reaction was diluted with EtOAc and washed with brine. The organic phase was separated, dried over sodium sulfate and the solvent was removed in vacuo. The crude material was purified by Biotage Isolera. LCMS calculated for C₂₃H₃₁IN₃O₃Si (M+H)⁺: m/z=552.1; found: 552.1.

Step 3. N-(2,6-Dimethylphenyl)-6-methoxy-3-(H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxamide

embedded image

N-(2,6-Dimethylphenyl)-3-iodo-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxamide (1.76 g, 3.19 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (1.4 g, 4.8 mmol), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine(2′-aminobiphenyl-2-yl)(chloro)palladium (0.251 g, 0.319 mmol) and K₃PO₄(1.016 g, 4.79 mmol) were placed in a flask with septum. The reaction was evacuated and backfilled with nitrogen three times. Then 1,4-dioxane (12 ml) and water (3 ml) were added, and the reaction mixture was stirred at 60° C. for 1 h. After addition of sodium carbonate (0.676 g, 6.38 mmol) and water (1 ml), the reaction mixture was stirred at 110° C. for an additional 1 h. After cooling to r.t., the reaction mixture was diluted with EtOAc and water. The organic phase was separated, dried over sodium sulfate and the solvent was removed in vacuo. The resultant crude product was purified by Biotage Isolera. LCMS calculated for C₂₆H₃₄N₅O₃Si (M+H)⁺: m/z=492.1; found: 492.3.

Step 4. 2-(4-(5-((2,6-Dimethylphenyl)carbamoyl)-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1H-pyrazol-1-yl)acetic acid

embedded image

A solution of N-(2,6-dimethylphenyl)-6-methoxy-3-(1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxamide (98 mg, 0.199 mmol), methyl 2-bromoacetate (20.76 μl, 0.219 mmol) and cesium carbonate (130 mg, 0.399 mmol) in acetonitrile (2 ml) was stirred at 80° C. for 1 h. After cooling to r.t., the reaction mixture was quenched with water, and the desired product was extracted with DCM. The organic phase was washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The crude material was purified by Biotage Isolera.

To a solution of the resultant purified material in a mixture of THF (1 ml), MeOH (1 ml), and water (1 ml) was added sodium hydroxide (1M solution in water, 1 ml, 1 mmol). The reaction mixture was stirred at r.t. for 1 h before the pH was adjusted to pH 5 using 1M HCl solution. The precipitated solid was collected by filtration, washed with MeOH and ether, and air-dried overnight. LCMS calculated for C₂₈H₃₆N₅O₅Si (M+H)⁺: m/z=550.1; found: 550.3.

Step 5. N-(2,6-Dimethylphenyl)-3-(1-(2-(ethylamino)-2-oxoethyl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide

BOP (12 mg, 0.027 mmol) was added to a solution of 2-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1H-pyrazol-1-yl)acetic acid (10 mg, 0.018 mmol), ethanamine (0.82 mg, 0.018 mmol) and DIPEA (10 μl, 0.055 mmol) in N,N-dimethylformamide (0.4 ml). The reaction mixture was stirred at 50° C. for 1 h before it was diluted with EtOAc and washed with brine. The solvent was removed in vacuo, and the resultant material was dissolved in a mixture of DCM (1 ml) and TFA (0.5 ml) and the reaction was stirred at r.t. for 15 min. The solvents were then removed in vacuo and the crude material was dissolved in MeOH (1 ml) and water solution of ammonia (0.5 ml). The reaction mixture was stirred at r.t. for 10 min, then diluted with CH₃CN and water and purified with prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 m/min). The product was isolated as the TFA salt. LCMS calculated for C₂₄H₂₇N₆O₃(M+H)⁺: m/z=447.1; found: 447.3.

Example 20. 3-(4-(4-Acetylpiperazin-1-yl)phenyl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

Step 1. Methyl 3-iodo-6-methoxy-1-(4-methoxybenzyl)-1H-indazole-5-carboxylate

embedded image

NIS (1.27 g, 5.65 mmol) was added to a solution of methyl 6-methoxy-1H-indazole-5-carboxylate (1.06 g, 5.14 mmol) in DMF (10 ml). After stirring at 60° C. for 2 h, cesium carbonate (3.35 g, 10.28 mmol) and 1-(chloromethyl)-4-methoxybenzene (0.97 g, 6.17 mmol) were added to the above solution at r.t. The solution was stirred at 80° C. for 1 h. At completion, the reaction mixture was cooled to r.t. and partitioned between EtOAc and water. The organic phase was separated, dried over sodium sulfate and the solvent was removed in vacuo. The resultant crude product was purified by Biotage Isolera. LCMS calculated for C₁₈H₁₈IN₂O₄(M+H)⁺: m/z=453.1; found: 453.1.

Step 2. N-(2,6-Dimethylphenyl)-3-iodo-6-methoxy-1-(4-methoxybenzyl)-1H-indazole-S-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 19, with methyl 3-iodo-6-methoxy-1-(4-methoxybenzyl)-1H-indazole-5-carboxylate replacing methyl 3-iodo-6-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylate in Step 2. LCMS calculated for C₂₅H₂₅IN₃O₃(M+H)⁺: m/z=542.1; found: 542.2.

Step 3. 3-(4-(4-Acetylpiperazin-1-yl)phenyl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide

N-(2,6-Dimethylphenyl)-3-iodo-6-methoxy-1-(4-methoxybenzyl)-1H-indazole-5-carboxamide (15 mg, 0.028 mmol), 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one (12 mg, 0.036 mmol), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium (2 mg, 2.77 μmol) and K₃PO₄(9 mg, 0.042 mmol) were placed in a vial with septum. The vial was evacuated and backfilled with nitrogen three times, then 1,4-dioxane (1 ml) and water (0.2 mL) were added, and the reaction mixture was stirred at 60° C. for 1 h. At completion, the reaction was diluted with EtOAc and water. The organic phase was separated, washed with brine, dried over sodium sulfate and concentrated in vacuo. Then TFA (1 ml) was added and the reaction mixture was heated at 100° C. for 2 h. After cooling to r.t., the reaction was diluted with CH₃CN and water and purified with prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for C₂₉H₃₂N₅O₃(M+H)⁺: m/z=498.1; found: 498.3.

Example 21. N-(2,6-Dimethylphenyl)-6-methoxy-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₈H₃₂N₅O₂(M+H)⁺: m/z=470.1; found: 470.3.

Example 22. 3-(1-(1-(Dimethylcarbamoyl)azetidin-3-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

Step 1. 3-(1-(Azetidin-3-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-J-(4-methoxybenzyl)-1H-indazole-5-carboxamide

embedded image

N-(2,6-Dimethylphenyl)-3-iodo-6-methoxy-1-(4-methoxybenzyl)-1H-indazole-5-carboxamide (500 mg, 0.924 mmol), tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate (419 mg, 1.201 mmol), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium (73 mg, 0.092 mmol) and K₃PO₄(294 mg, 1.385 mmol) were placed in a vial with a septum. The vial was evacuated and backfilled with nitrogen three times, then 1,4-dioxane (2 ml) and water (0.2 mL) were added, and the reaction mixture was stirred at 60° C. for 1 h. At completion the reaction was diluted with EtOAc and water. The organic phase was separated, washed with brine, dried over sodium sulfate and concentrated in vacuo. The crude material was purified by Biotage Isolera to give the Boc-protected intermediate. TFA (1 ml) and DCM (1 ml) were added to the intermediate and the reaction mixture was stirred at r.t. for 1 h. After the solvents were evaporated in vacuo, DCM was added and the reaction was washed with NaHCO₃solution, brine, dried over sodium sulfate and concentrated in vacuo. The resultant material was used in the next step without further purification. LCMS calculated for C₃₁H₃₃N₆O₃(M+H)⁺: m/z=537.1; found: 537.3.

Step 2. 3-(1-(1-(Dimethylcarbamoyl)azetidin-3-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide

Dimethylcarbamic chloride (3 mg, 0.028 mmol) was added to a solution of 3-(1-(azetidin-3-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1-(4-methoxybenzyl)-1H-indazole-5-carboxamide (15.0 mg, 0.028 mmol) and TEA (12 μl, 0.084 mmol) in dioxane (0.5 ml). The reaction mixture was stirred at r.t. for 1h, and then was quenched with water. The desired product was extracted with DCM, dried over sodium sulfate and concentrated in vacuo. Triflic acid (0.5 ml) was added to the resultant residue and the reaction was stirred at 50° C. for 2 h. The reaction was then diluted with CH₃CN and water and purified with prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 m/min). The product was isolated as the TFA salt. LCMS calculated for C₂₆H3N₇O₃(M+H)⁺: m/z=488.1; found: 488.2.

Example 23. Ethyl 3-(4-(5-((2,6-Dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate

embedded image

This compound was prepared according to the procedures described in Example 22 with ethyl carbonochloridate replacing dimethylcarbamic chloride in Step 2. The product was isolated as the TFA salt. LCMS calculated for C₂₆H₂₉N₆O₄(M+H)⁺: m/z=489.1; found: 489.2.

Example 24. Methyl 4-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate

embedded image

Step 1. N-(2,6-Dimethylphenyl)-6-methoxy-1-(4-methoxybenzyl)-3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 22 with tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate replacing tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate in Step 1. LCMS calculated for C₃₃H₃₇N₆O₃(M+H)⁺: m/z=565.1; found: 565.4.

Step 2. Methyl 4-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate

Methyl chloroformate (1.7 mg, 0.018 mmol) was added to a solution of N-(2,6-dimethylphenyl)-6-methoxy-1-(4-methoxybenzyl)-3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide (10.0 mg, 0.018 mmol) and TEA (15 μl, 0.106 mmol) in dioxane (0.5 ml). The reaction mixture was stirred at r.t. for 1h, and then quenched with water. The desired product was extracted with DCM, dried over sodium sulfate and concentrated in vacuo. Triflic acid (0.5 ml) was added to the resultant residue and the reaction was stirred at r.t. for 2 h. The reaction was then diluted with CH₃CN and water and purified with prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 m/min). The product was isolated as the TFA salt. LCMS calculated for C₂₇H₃₁N₆O₄(M+H)⁺: m/z=503.1; found: 503.2.

Example 25. 3-(1-(1-Acetylpiperidin-4-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 24 with acetyl chloride replacing methyl chloroformate in Step 2. The product was isolated as the TFA salt. LCMS calculated for C₂₇H₃₁N₆O₃(M+H)⁺: m/z=487.1; found: 487.2.

Example 26. N-(2, 6-Dimethylphenyl)-6-methoxy-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 1. The product was isolated as the TFA salt. LCMS calculated for C₂₇H₃₁N₆O₂(M+H)⁺: m/z=471.1; found: 471.2.

Example 27. N-(2,6-Dimethyl-4-(methylsulfonamido)phenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

Step 1. N-(2,6-Dimethyl-4-nitrophenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxamide

embedded image

To a solution of 6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxylic acid (Example 1, Step 4, 200 mg, 0.5 mmol) in DCM (10 ml) was added oxalyl chloride (87 μl, 1 mmol), followed by the catalytic amount of DMF. After stirring at r.t. for 30 min, the reaction solution was concentrated in vacuo. To the resulting residue was added DCM (10 ml) and the solution was cooled to 0° C. 2,6-dimethyl-4-nitroaniline (83 mg, 0.497 mmol) and TEA (208 μl, 1.491 mmol) were added. The reaction mixture was stirred at r.t. for 1 h, and quenched with water. The product was extracted with DCM, dried over sodium sulfate and concentrated in vacuo. The crude material was purified by Biotage Isolera to give the desired compound. LCMS calculated for C₂₇H₃₅N₆O₅Si (M+H)⁺: m/z=551.1; found: 551.3.

Step 2. N-(4-Amino-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxamide

embedded image

A mixture of N-(2,6-dimethyl-4-nitrophenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxamide (86 mg, 0.156 mmol) and Pd/C (17 mg, 0.016 mmol) in MeOH (5 ml) was stirred at r.t. for 2 h under an atmosphere of hydrogen (balloon). The reaction was filtered through a pad of Celite and the solvent was removed in vacuo. The resultant crude product was used in the next step without further purification. LCMS calculated for C₂₇H₃₇N₆O₃Si (M+H)⁺: m/z=521.1; found: 521.3.

Step 3. N-(2,6-Dimethyl-4-(methylsulfonamido)phenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

Methanesulfonyl chloride (3 mg, 0.029 mmol) was added to a solution of N-(4-amino-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxamide (10 mg, 0.019 mmol) and TEA (8 μl, 0.058 mmol) in dioxane (0.5 ml). The reaction mixture was stirred at r.t. for 1 h, and then quenched with water. The product was extracted with DCM, dried over sodium sulfate and concentrated in vacuo. The resultant material was dissolved in a mixture of DCM (1 ml) and TFA (0.5 ml) and the solution was stirred at r.t. for 15 min. Volitiles were removed in vacuo and the crude material was dissolved in MeOH (1 ml) and water solution of ammonia (0.5 ml). The reaction mixture was stirred at r.t. for 10 min, then diluted with CH₃CN and water and purified with prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 L/min). The product was isolated as the TFA salt. LCMS calculated for C₂₂H₂₅N₆O₄S (M+H)⁺: m/z=469.1; found: 469.2.

Example 28. N-(4-Acetamido-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 27 with acetyl chloride replacing methanesulfonyl chloride in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₃H₂₅N₆O₃(M+H)⁺: m/z=433.1; found: 433.2.

Example 29. N-(4-(Dimethylamino)-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

To a solution of N-(4-amino-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-5-carboxamide (Example 27, Step 2, 10 mg, 0.019 mmol) and formaldehyde (30% in water, 3.84 mg, 0.038 mmol) in THF (0.50 ml) was added sodium triacetoxyborohydride (8.14 mg, 0.038 mmol). The reaction mixture was stirred at r.t. overnight, and then quenched with water. The desired product was extracted with DCM, dried over sodium sulfate and concentrated in vacuo. The resultant material was dissolved in a mixture of DCM (1 ml) and TFA (0.5 ml) and the reaction was stirred at r.t. for 15 min. Volitiles were removed in vacuo and the crude material was dissolved in MeOH (1 ml) and water solution of ammonia (0.5 ml). The reaction mixture was stirred at r.t. for 10 min, then diluted with CH₃CN and water and purified with prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 m/min). The product was isolated as the TFA salt. LCMS calculated for C₂₃H₂₇N₆O₂(M+H)⁺: m/z=419.1; found: 419.2.

Example 30. N-(2,6-Dimethylphenyl)-3-(1-(1-(ethylcarbamoyl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 22 with isocyanatoethane replacing dimethylcarbamic chloride in Step 2. The product was isolated as the TFA salt. LCMS calculated for C₂₆H₃₀N₇O₃(M+H)⁺: m/z=488.1; found: 488.3.

Example 31. Methyl 3-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate

embedded image

This compound was prepared according to the procedures described in Example 22 with methyl chloroformate replacing dimethylcarbamic chloride in Step 2. The product was isolated as the TFA salt. LCMS calculated for C₂₅H₂₇N₆O₄(M+H)⁺: m/z=475.1; found: 475.3.

Example 32. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-(1-(methylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 22 with methanesulfonyl chloride replacing dimethylcarbamic chloride in Step 2. The product was isolated as the TFA salt. LCMS calculated for C₂₄H₂₇N₆O₄S (M+H)⁺: m/z=495.1; found: 495.2.

Example 33. 3-(1-(1-Acetylazetidin-3-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 22 with acetyl chloride replacing dimethylcarbamic chloride in Step 2. The product was isolated as the TFA salt. LCMS calculated for C₂₅H₂₇N₆O₃(M+H)⁺: m/z=459.1; found: 459.2.

Example 34. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₆H₃₁N₆O₂(M+H)⁺: m/z=459.1; found: 459.3.

Example 35. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₅H₂₈N₅O₃(M+H)⁺: m/z=446.1; found: 446.3.

Example 36. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 1-(tetrahydrofuran-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₄H₂₆N₅O₃(M+H)⁺: m/z=432.1; found: 432.2.

Example 37. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl)pyridine replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₆H₂₅N₆O₂(M+H)⁺: m/z=453.1; found: 453.3. ¹H NMR (500 MHz, DMSO-d6) δ 9.53-9.44 (s, 1H), 8.61-8.56 (d, J=4.3 Hz, 1H), 8.57-8.55 (s, 1H), 8.32-8.26 (s, 1H), 8.07-8.01 (s, 1H), 7.89-7.80 (td, J=7.7, 1.8 Hz, 1H), 7.42-7.34 (dd, J=6.9, 5.5 Hz, 1H), 7.21-7.15 (d, J=7.9 Hz, 1H), 7.14-7.11 (s, 3H), 7.11-7.09 (s, 1H), 5.63-5.50 (s, 2H), 4.04-3.95 (s, 3H), 2.31-2.24 (s, 6H) ppm.

Example 38. N-(2,6-Dimethylphenyl)-3-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethan-1-ol replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₂H₂₄N₅O₃(M+H)⁺: m/z=406.1; found: 406.3.

Example 39. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-(piperidin-4-ylmethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with tert-butyl 4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₆H₃₁N₆O₂(M+H)⁺: m/z=459.1; found: 459.3.

Example 40. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethyl)morpholine replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₆H₃₁N₆O₃(M+H)⁺: m/z=475.1; found: 475.2.

Example 41. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 3-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl)pyridine replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₆H₂₅N₆O₂(M+H)⁺: m/z=453.1; found: 453.2.

Example 42. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)pyridine replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₅H₂₃N₆O₂(M+H)⁺: m/z=439.1; found: 439.2.

Example 43. 3-(1-Cyclobutyl-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 1-cyclobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₄H₂₆N₅O₂(M+H)⁺: m/z=416.1; found: 416.2.

Example 44. 3-(1-Cyclopropyl-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₃H₂₄N₅O₂(M+H)⁺: m/z=402.1; found: 402.2.

Example 45. N-(2,6-Dimethylphenyl)-6-methoxy-3-(1-propyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide

embedded image

This compound was prepared according to the procedures described in Example 20 with 1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one in Step 3. The product was isolated as the TFA salt. LCMS calculated for C₂₃H₂₆N₅O₂(M+H)⁺: m/z=404.1; found: 404.2.

Example A
FGFR Enzymatic Assay

The inhibitor potency of the exemplified compounds was measured in an enzyme assay that measures peptide phosphorylation using FRET measurements to detect product formation. Inhibitors were serially diluted in DMSO and a volume of 0.5 μL was transferred to the wells of a 384-well plate. For FGFR3, a 10 μL volume of FGFR3 enzyme (Millipore) diluted in assay buffer (50 mM HEPES, 10 mM MgCl₂, 1 mM EGTA, 0.01% Tween-20, 5 mM DTT, pH 7.5) was added to the plate and pre-incubated for a time between 5-10 minutes and up to 4 hours. Appropriate controls (enzyme blank and enzyme with no inhibitor) were included on the plate. The assay was initiated by the addition of a 10 μL solution containing biotinylated EQEDEPEGDYFEWLE peptide substrate (SEQ ID NO: 1) and ATP (final concentrations of 500 nM and 140 μM respectively) in assay buffer to the wells. The plate was incubated at 25° C. for 1 hr. The reactions were ended with the addition of 10 μL/well of quench solution (50 mM Tris, 150 mM NaCl, 0.5 mg/mL BSA, pH 7.8; 30 mM EDTA with Perkin Elmer Lance Reagents at 3.75 nM Eu-antibody PY20 and 180 nM APC-Streptavidin). The plate was allowed to equilibrate for ˜1 hr before scanning the wells on a PheraStar plate reader (BMG Labtech).

GraphPad prism3 was used to analyze the data. The IC₅₀values were derived by fitting the data to the equation for a sigmoidal dose-response with a variable slope. Y=Bottom+(Top-Bottom)/(1+10{circumflex over ( )}((Log IC₅₀−X)*HillSlope)) where X is the logarithm of concentration and Y is the response. Compounds having an IC₅₀of 1 μM or less are considered active.

Table 1 provides IC₅₀data for compounds of the invention assayed in the FGFR Enzymatic Assay after dilution in assay buffer, added to the plate and pre-incubated for 4 hours.

The symbol: “+” indicates an IC₅₀less than 10 nM; “++” indicates an IC₅₀greater than or equal to 10 nM but less than 30 nM; “+++” indicates an ICs greater than or equal to 30 nM but less than 200 nM; and “++++” indicates an ICs greater than or equal to 200 nM.

TABLE 1

Example
FGFR3, nM

1
+

2
+

3
+

4
+

5
+

6
+

7
+

8
+

9
+++

10
+++

11
++

12
++++

13
+++

14
++++

15
++++

16
++++

17
+

18
++

19
++

20
+

21
+

22
+

23
+

24
+

25
+

26
+

27
++

28
+++

29
+++

30
+

31
+

32
+

33
+

34
+

35
+

36
+

37
+

38
++

39
++

40
++

41
++

42
+++

43
+

44
+

45
+

Example B: Luminescent Viability Assay

RT112 cells are purchased from ATCC (Manassas, Va.) and maintained in RPMI, 10% FBS (Gibc o/Life Technologies). To measure the effect of test compounds on the viability of cells, the cells are plated with RPMI 10% FBS (5×10³cells/well/in 50 μL) into black 96-well Greiner polystyrene in the presence or absence of 50 ul of a concentration range of test compounds. After 3 days, 100 ul of CellTiter-Glo Reagent (Promega) is added. Luminescence is read with a TopCount (PerkinElmer). IC₅₀determination is performed by fitting the curve of percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.

Example C: pFGFR2 and pFGFR1,3 Functional Cell HTRF Assay

To measure phosphorylated Fibroblast Growth Factor Receptor 2 (FGFR2), KATOIII cells (Human Gastric Carcinoma) are purchased from ATCC and maintained in Iscove's with 20% FBS (Gibco/Life Technologies). For the pFGFR2 assay, KATOIII cells are plated overnight in 5% FBS and Iscove's medium at 5×10⁴cells/well into Corning 96-well flat-bottom tissue culture treated plates. The next morning, 50 μl of fresh media with 0.5% FBS is incubated in the presence or absence of a concentration range of test compounds also at 50 ul, for 1 hour at 37° C., 5% CO2. Cell are washed with PBS, lysed with Cell Signaling Lysis Buffer with standard Protease inhibitors for 45 min at room temperature. 4 μl total of Cis Bio Anti Phospho-YAP d2 and Cis Bio Anti Phospho-YAP Cryptate together are added to the lysate and mixed well (following directions of the kit). 16 μl is then transferred to 384 well Greiner white plates and stored at 4° C. overnight in the dark. Plates are read on the Pherastar plate reader at 665 nm and 620 nm wavelengths. IC₅₀determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.

To measure phosphorylated Fibroblast Growth Factor Receptor 3 (FGFR3), in house stable cell lines BAF3-TEL-FGFR1 or BAF3-TEL-FGFR3 are maintained in RPMI with 10% FBS and 1 ug/ml puromycin (Gibco/Life Technologies). For the assay, 12 nl of BAF3-TEL-FGFR1 or BAF3-TEL-FGFR3 cells in serum free and puromycin free RPMI media at 1×10⁶cell/ml are added to 384 Greiner white plate already containing 20 nl dots of compounds at a concentration range. The plates are gently shaken (100 rpm) for 2 minutes at room temperature to mix well and incubate for 2 hours in a single layer at 37° C., 5% CO2. 4 l/well of 1/25 dilution of lysis buffer #3 (Cis Bio) is added with standard Protease inhibitors and shaken at 200 rpm at room temperature for 20 minutes. 4 μl total of the Cis Bio Tb-pFGFR Ab (10 ng) and d2-FGFR3 (ing) together are added to the lysate and mixed well. The plates are sealed and incubated at room temperature overnight in the dark. The plates are read on the Pherastar plate reader at 665 nm and 620 nm wavelengths. IC₅₀determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.

Example D: pFGFR3 Functional Whole Blood HTRF Assay

To measure phosphorylated Fibroblast Growth Factor Receptor 3 (FGFR3) in a whole blood assay, in house stable cell lines BAF3-TEL-FGFR3 are maintained in RPMI with 10% FBS and 1 μg/ml puromycin (Gibco/Life Technologies). For the assay, 100 ul BAF3-TEL-FGFR3 cells in 10% FBS and puromycin free RPMI media at 5×10⁴cell/well are added to fibronectin coated 96 well tissue culture plate (5 ug/ml) overnight at 37° C., 5% CO2. The next day, serum is separated from the top of the blood by a low speed spin, 1200, RPM, and heat inactivated by incubating at 56° C. for 15 minutes. 30 μl of the cooled serum is added to a 96 well plate pre dotted with 70 nM dots of compounds at a concentration range. Cell plates are washed gently with media, all the blood/compound mixture is added to the plates, and the plates are incubated for 2 hours at 37° C., 5% CO2. Blood from the plate is gently washed twice by adding media to the side of the wells and then dumping media from the plate, and allowing the plate to briefly sit on a paper towel to drain. 70 μl/well of 1× of lysis buffer #1 (Cis Bio) are added with standard Protease inhibitors, and are shaken at 400 rpm at room temperature for 30 minutes. Following lysis, the plate is spun down for 5 minutes and 16 uL of lysate is transferred into a 384-well small volume plate. 4 μl total of the Cis Bio Tb-pFGFR Ab (Ong) and d2-FGFR3 (Ing) together are added to the lysate and mixed well. The plates are sealed and incubated at room temperature overnight in the dark. Plates are read on the Pherastar plate reader at 665 nm and 620 nm wavelengths. IC₅₀determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.

Example E: KATOIII Whole Blood pFGFR2a ELISA Assay

To measure tyrosine-phosphorylated Fibroblast Growth Factor Receptor 2 alpha (FGFR2a) in KATO III spiked whole blood assay, KATO III cells are purchased from ATCC and maintained in Iscove's medium with 20% FBS (Gibco/Life Technologies). To measure the inhibition of FGFR2α activity of test compounds, the cells are resuspended with Iscove's, 0.2% FBS at 5×10⁶cells/ml. 50 μL of the cells are then spiked into a 96-deep well 2 ml polypropylene assay block (Costar) in the presence or absence of a concentration range of test compounds and 300 ul human heparinized whole blood (Biological Specialty Corp, Colmar Pa.). After 4 hours incubation in 37° C., the red cells are lysed using Qiagen EL buffer and the cell lysates are resuspended in lysis buffer (Cell Signaling) containing standard protease inhibitor cocktail (Calbiochem/EMD) and PMSF (Sigma) for 30 minutes ice. The lysates are transferred to a standard V bottom propylene tissue culture plate and frozen overnight at −80C. Samples are tested an in an R & D Systems DuoSet IC Human Phospho-FGF R2α ELISA and the plate is measured using a SpectraMax M5 microplate set to 450 nm with a wavelength correction of 540. IC₅₀determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.

Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.

Claims

1. A compound of Formula (I):
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy1 is 5 or 6-membered heteroaryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10.
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy1 is 5-membered heteroaryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10.
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy1 is pyrazolyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10.
5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy1 is 6-membered heteroaryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10.
6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy1 is pyridinyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10.
7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy1 is phenyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10.
8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy1 is selected from pyrazolyl, pyridinyl, and phenyl; each of which is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10.
9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R10 is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; wherein said C1-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11.
10. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein each R10 is independently selected from C1-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11.
11. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein each R10 is independently selected from methyl, ethyl, propyl, cyclopropyl, cyclobutyl, piperazinyl, azetidinyl, piperidinyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, and pyridinyl; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R10.
12. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein each R10 is independently selected from methyl, propyl, 2-hydroxyethyl, cyclopropyl, cyclobutyl, CH2C(O)NHCH2CH3, 4-acetylpiperazin-1-yl, 4-methylpiperazin-1-yl, 1-(dimethylcarbamoyl)azetidin-3-yl, 1-acetylpiperidin-4-yl, 4-methylpiperazin-1-yl, 1-(ethylcarbamoyl)azetidin-3-yl, 1-(methylsulfonyl)azetidin-3-yl, 1-acetylazetidin-3-yl, 1-methylpiperidin-4-yl, tetrahydro-2H-pyran-4-yl, tetrahydrofuran-3-yl, pyridin-2-ylmethyl, piperidin-4-ylmethyl, 2-morpholinoethyl, pyridin-3-ylmethyl, pyridin-2-yl, 1-(ethoxycarbonyl)azetidin-3-yl, 1-(methoxycarbonyl)piperidin-4-yl, and 1-(methoxycarbonyl)azetidin-3-yl.
13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R10 is methyl.
14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R11 is independently selected from C1-6 alkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, ORa3, C(O)NRc3Rd3, C(O)Rb3, C(O)ORa3, and S(O)2Rb3.
15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R11 is C1-6 alkyl.
16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R1 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, and ORa5.
17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein CyA is C6-10 aryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R20.
18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein CyA is phenyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R20.
19. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein CyA is selected from 2,6-dimethylphenyl, 2-chloro-6-fluorophenyl, 2-chloro-6-methylphenyl, 2-methyl-6-(trifluoromethyl)phenyl, 4-fluoro-2,6-dimethylphenyl, 2-ethyl-6-methylphenyl, 2,6-diethylphenyl, 2-fluoro-6-methylphenyl, 2-methoxy-6-methylphenyl, 4-methoxy-2,6-dimethylphenyl, 4-cyano-2,6-dimethylphenyl, 2,6-dimethyl-4-(methylsulfonamido)phenyl, 4-acetamido-2,6-dimethylphenyl, and 4-(dimethylamino)-2,6-dimethylphenyl.
20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R20 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein said C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21.
21. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein each R20 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, OR2, CN, NRc2Rd2, NRc2C(O)Rb2, and NRc2S(O)2Rb2; wherein said C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21.
22. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein, each R20 is independently selected from methyl, ethyl, methoxy, CF3, CN, F, Cl, N(CH3)2, NHS(O)2CH3, and NHC(O)CH3.
23. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R21 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa4, SRa4 and NRc4Rd4; wherein said C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22.
24. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R22 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa6, and NRc6Rd6.
25. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from halo, C1-6 alkyl, and ORa.
26. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from Cl, methyl, and methoxy.
27. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is methoxy.
28. The compound of claim 1, having Formula (Ha):
29. The compound of claim 1, having Formula (IIb):
30. The compound of claim 1, having Formula (IIIa):
31. The compound of claim 1, having Formula (IIIb):
32. The compound of claim 1, having Formula (IV):
33. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Cy1 is 5-membered heteroaryl, wherein the 5-membered heteroaryl has at least one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from O, S and N; wherein no more than 2 of the ring forming heteroatoms of the 5-membered heteroaryl is N; wherein each N and S of the 5-membered heteroaryl is optionally oxidized; wherein a ring-forming carbon atom of 5-membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10;CyA is C6-10 aryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R20;R1 is selected from halo, CN, C1-6 alkyl, C3-4 cycloalkyl, azetidinyl, OR and NRcRd; wherein the C1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Rg;each R10 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, D, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(═NRe1)Rb1, C(═NORa1)Rb1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11;each R11 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, D, CN, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R2;each R12 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)ORa5, NRc5S(O)Rb5, NRc5S(O)2Rb5, NRc5S(O)2NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, and S(O)2NRc5Rd5; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;each R20 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, D, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(═NRe2)Rb2, C(═NORa2)Rb2, C(═NRe2)NRc2Rd2, NRc2C(═NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21;or two adjacent R20 substituents on the CyA ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered cycloalkyl ring or fused 5- or 6-membered heterocycloalkyl ring, wherein each fused 5- or 6-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2, or 3 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6-membered cycloalkyl ring and fused 5- or 6-membered heterocycloalkyl ring, are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R21;each R21 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, D, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rd4, and S(O)2NRc4Rd4; wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22;or two R21 substituents taken together with the carbon atom to which they are attached form a spiro 3-7-membered heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring; wherein each spiro 3-7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each spiro 3-7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the spiro 3-7 membered heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R22;each R22 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, ORa6, SRa6, C(O)Rb6, C(O)NRc6Rd6, C(O)ORa6, NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, and S(O)2NRc6Rd6; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;each Ra, Rc and Rd is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 haloalkyl; wherein said C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;each Ra1, Rc1 and Rd1 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11;or any Rc1 and Rd1 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11;each Rb1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11;each Re1 is independently selected from H, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylthio, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C1-6 alkylaminosulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6alkyl)carbamyl, aminosulfonyl, C1-6alkylaminosulfonyl and di(C1-6alkyl)aminosulfonyl;each Ra2, Rc2 and Rd2 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21;or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R21;each Rb2 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21;each Re2 is independently selected from H, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylthio, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C1-6 alkylaminosulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6alkyl)carbamyl, aminosulfonyl, C1-6alkylaminosulfonyl and di(C1-6alkyl)aminosulfonyl;each Ra3, Rc3 and Rd3 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C1-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R12;or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R2;each Rb3 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C1-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R2;each Ra4, Rc4 and Rd4 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C1-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22;or any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R22;each Rb4 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C1-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22;each Ra5, Rc5 and Rd5 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 haloalkyl; wherein said C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;or any Rc5 and Rd5 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;each Rb5 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 haloalkyl; wherein said C1-6 alkyl C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;each Ra6, Rc6 and Rd6 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 haloalkyl; wherein said C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;each Rb6 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl; wherein said C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; and
34. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Cy1 is pyrazolyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R10;CyA is phenyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R20;R1 is selected from halo, CN, C1-3 alkyl, and ORa; wherein the C1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Rg;each R10 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene, 5-10 membered heteroaryl-C1-3 alkylene, halo, D, CN, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-3 alkylene, 4-10 membered heterocycloalkyl-C1-3 alkylene, C6-10 aryl-C1-3 alkylene and 5-10 membered heteroaryl-C1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11;each R11 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R12;each R12 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, D, CN, OR, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, NRc5Rd5, and S(O)2Rb5; wherein said C1-6 alkyl, is each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;each R20 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halo, D, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, Rc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21;each R21 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, D, CN, ORa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, NRc4Rd4, and S(O)2Rb4; wherein said C1-6 alkyl, is each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22;each R22 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, D, CN, OR6, and NRc6Rd6; wherein said C1-6 alkyl, is each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;Ra is selected from H, C1-3 alkyl, and C1-3 haloalkyl;each Ra1, Rc1 and Rd1 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11;or any Rc1 and Rd1 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11;each Rb1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R11;each Ra2, Rc2 and Rd2, is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21;or any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R21;each Rb2 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R21;each Ra3, Rc3 and Rd3, is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C1-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R12;or any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R12;each Rb3 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl;wherein said C1-6 alkyl C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R12;each Ra4, Rc4 and Rd4, is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 haloalkyl; wherein said C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22;each Rb4 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl; wherein said C1-6 alkyl C2-6 alkenyl, and C24 alkynyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22;each Ra5, Rc5 and Rd5, is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 haloalkyl; wherein said C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;each Rb5 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 haloalkyl; wherein said C1-6 alkyl C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg;each Ra6, Rc6 and Rd6, is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 haloalkyl; wherein said C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; andeach Rg is independently selected from OH, NO2, CN, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-2 alkylene, C1-6 alkoxy, C1-6 haloalkoxy, C1-3 alkoxy-C1-3 alkyl, C1-3 alkoxy-C1-3 alkoxy, HO—C1-3 alkoxy, HO—C1-3 alkyl, cyano-C1-3 alkyl, H2N—C1-3alkyl, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, thio, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, carboxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, Cia alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, aminosulfonylamino, C1-6alkylaminosulfonylamino, di(C1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C1-6 alkylaminocarbonylamino, and di(C1-6 alkyl)aminocarbonylamino.
35. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Cy1 is pyrazolyl, pyridinyl, or phenyl, each of which is optionally substituted with R10;CyA is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from R20;R1 is selected from halo, C1-3 alkyl, and ORa;each R10 is independently selected from C1-6 alkyl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl; each of which is optionally substituted with R11;R11 is independently selected from C1-6 alkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, ORa3, C(O)NRc3Rd3, C(O)Rb3, C(O)ORa3, and S(O)2Rb3;each R20 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, OR2, CN, NRc2Rd2, NRc2C(O)Rb2, and NRc2S(O)2Rb2; wherein said C1-6 alkyl is optionally substituted with R21;R21 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa4, SRa4 and NRc4Rd4; wherein said C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R22;each R22 is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa6, and NRc6Rd6;Ra is selected from H, C1-3 alkyl, and C1-3 haloalkyl;each Ra2, Rc2 and Rd2, is independently selected from H, C1-6 alkyl, and C1-6 haloalkyl;wherein said C1-6 alkyl;each Rb2 is independently selected from C1-6 alkyl;each Ra3, Rc3 and Rd3 is independently selected from H, C1-6 alkyl, and C1-6 haloalkyl;each Rb3 is independently selected from C1-6 alkyl and C1-6 haloalkyl;each Ra4, Rc4 and Rd4 is independently selected from H, C1-6 alkyl, and C1-6 haloalkyl; andeach Ra6, Rc6 and Rd6 is independently selected from H, C1-6 alkyl, and C1-6 haloalkyl.
36. The compound of claim 1, wherein the compound is selected from: N-(2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2-chloro-6-fluorophenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2-chloro-6-methylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-6-(trifluoromethyl)phenyl)-1H-indazole-5-carboxamide;N-(4-fluoro-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2-ethyl-6-methylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-diethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2-fluoro-6-methylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;6-methoxy-N-(2-methoxy-6-methylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;6-methoxy-N-(4-methoxy-2,6-dimethylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(4-cyano-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;6-chloro-N-(2,6-dimethylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2-fluoro-6-methylphenyl)-6-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;6-chloro-N-(2-fluoro-6-methylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;6-chloro-N-(2-chloro-6-fluorophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2-chloro-6-fluorophenyl)-3-(1-cyclobutyl-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;N-(2-chloro-6-fluorophenyl)-3-(1-cyclopropyl-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-3-(1-(2-(ethylamino)-2-oxoethyl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;3-(4-(4-acetylpiperazin-1-yl)phenyl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methoxy-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-indazole-5-carboxamide;3-(1-(1-(dimethylcarbamoyl)azetidin-3-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;ethyl 3-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate;methyl 4-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate;3-(1-(1-acetylpiperidin-4-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;N-(2, 6-dimethylphenyl)-6-methoxy-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethyl-4-(methylsulfonamido)phenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(4-acetamido-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(4-(dimethylamino)-2,6-dimethylphenyl)-6-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-3-(1-(1-(ethylcarbamoyl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;methyl 3-(4-(5-((2,6-dimethylphenyl)carbamoyl)-6-methoxy-1H-indazol-3-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate;N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(1-(methylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;3-(1-(1-acetylazetidin-3-yl)-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-3-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-6-methoxy-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(piperidin-4-ylmethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;N-(2,6-dimethylphenyl)-6-methoxy-3-(1-(pyridin-2-yl)-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide;3-(1-cyclobutyl-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide;3-(1-cyclopropyl-1H-pyrazol-4-yl)-N-(2,6-dimethylphenyl)-6-methoxy-1H-indazole-5-carboxamide; andN-(2,6-dimethylphenyl)-6-methoxy-3-(1-propyl-1H-pyrazol-4-yl)-1H-indazole-5-carboxamide,or a pharmaceutically acceptable salt of any of the aforementioned.
37. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
38. A method of inhibiting an FGFR3 enzyme comprising contacting said enzyme with a compound of claim 1 or a pharmaceutically acceptable salt thereof.
39. A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
40. A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in combination with another therapy or therapeutic agent.
41. The method of claim 39, wherein said cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.
42. The method of claim 39, wherein said cancer is selected from hepatocellular cancer, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdosarcoma.
43. A method for treating a skeletal or chondrocyte disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
44. The method of claim 43 wherein said skeletal or chondrocyte disorder is selected from achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndrome.

Provisional Applications (1)

	Number	Date	Country
	62908962	Oct 2019	US

BICYCLIC HETEROCYCLES AS FGFR INHIBITORS

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

Provisional Applications (1)